



(86) **Date de dépôt PCT/PCT Filing Date:** 2012/12/19
(87) **Date publication PCT/PCT Publication Date:** 2013/07/04
(45) **Date de délivrance/Issue Date:** 2016/09/06
(85) **Entrée phase nationale/National Entry:** 2014/06/27
(86) **N° demande PCT/PCT Application No.:** US 2012/070664
(87) **N° publication PCT/PCT Publication No.:** 2013/101598
(30) **Priorité/Priority:** 2011/12/27 (US61/580,474)

(51) **Cl.Int./Int.Cl. C07D 231/14** (2006.01),
A61K 31/415 (2006.01), **A61P 11/00** (2006.01),
C07D 231/38 (2006.01)


(72) **Inventeurs/Inventors:**
KANGASMETSA, JUSSI J., GB;
CARLING, WILLIAM R., GB;
MARTOS, JOSE L., GB;
WOODWARD, DAVID F., US;
WANG, JENNY W., US

(73) **Propriétaire/Owner:**
ALLERGAN, INC., US

(74) **Agent:** GOWLING WLG (CANADA) LLP

(54) **Titre : COMPOSES AGISSANT AU NIVEAU DE MULTIPLES RECEPTEURS DE PROSTAGLANDINE GENERANT UNE
REPONSE ANTI-INFLAMMATOIRE GENERALE**

(54) **Title: COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY
RESPONSE**



(57) **Abrégé/Abstract:**

The present invention provides a compound that is represented by the following general formula (A): wherein R_1 , R_2 , R_4 , R_5 , R_6 , R_7 , X , W , X and Y are as defined in the specification. The compounds may be administered to treat DP1, FP, EP1, TP and/or EP4 receptor mediated diseases or conditions.



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
4 July 2013 (04.07.2013)

(10) International Publication Number
WO 2013/101598 A1

(51) International Patent Classification:

C07D 231/14 (2006.01) *A61K 31/415* (2006.01)
C07D 231/38 (2006.01) *A61P 11/00* (2006.01)

(21) International Application Number:

PCT/US2012/070664

(22) International Filing Date:

19 December 2012 (19.12.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/580,474 27 December 2011 (27.12.2011) US

(71) Applicant: **ALLERGAN, INC.** [US/US]; 2525 Dupont Drive, Irvine, California 92612 (US).

(72) Inventors; and

(71) Applicants : **KANGASMETSA, Jussi J.** [SE/GB]; 9 Railway Cottages, Wendens Ambo, Saffron Essex CB11 4LA (GB). **CARLING, William R.** [GB/GB]; 28 Yeomans Close, Bishop's Stortford Hertfordshire CM23 4EU (GB). **MARTOS, Jose L.** [ES/GB]; 28 Newberry Side, Basildon Essex SS15 5XB (GB). **WOODWARD, David F.** [US/US]; 22736 Islamare Lane, Lake Forest, California 92630 (US). **WANG, Jenny W.** [US/US]; 2 Givernyn, Newport Coast, California 92657 (US).

(74) Agents: **WURST, John** et al.; Allergan, Inc., 2525 Dupont Drive, Irvine, California 92612 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*

(54) Title: COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE



(57) Abstract: The present invention provides a compound that is represented by the following general formula (A): wherein R₁, R₂, R₄, R₅, R₆, R₇, X, W, X and Y are as defined in the specification. The compounds may be administered to treat DP₁, FP, EP₁, TP and/or EP₄ receptor mediated diseases or conditions.

COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE

5

10

BACKGROUND OF THE INVENTION

This invention relates to compounds, to processes for their preparation, to pharmaceutical compositions containing them and to their use in medicine, in particular their use in the treatment of conditions mediated by the action of ligands for the DP₁, FP, TP, EP₁ and EP₄ prostaglandin (PG) receptors. The present compounds have the general structure shown below and act at different prostaglandin receptors to thereby provide a general anti-inflammatory response.

20

SUMMARY OF THE RELATED ART

The EP₁ receptor is a 7-transmembrane receptor and its natural ligand is the prostaglandin PGE₂. PGE₂ also has affinity for the other EP receptors (types EP₂, EP₃ and EP₄). The EP₁ receptor is associated with smooth muscle contraction, pain (in particular inflammatory, neuropathic and visceral), inflammation, allergic activities, renal regulation and gastric or enteric mucus secretion.

Prostaglandin E₂ (PGE₂) exerts allodynia through the EP₁ receptor subtype and hyperalgesia through EP₂ and EP₃ receptors in the mouse spinal cord. Furthermore, it has been shown that in the EP₁ knock-out mouse pain-sensitivity responses are reduced by approximately 50%. EP₁ receptor antagonist (ONO-8711) reduces hyperalgesia and allodynia in a rat model of chronic constriction injury and inhibits mechanical hyperalgesia in a rodent model of post-operative pain. The efficacy of EP₁ receptor antagonists in the treatment of visceral pain in a

human model of hypersensitivity has been demonstrated. Thus, selective prostaglandin ligands, agonists or antagonists, depending on which prostaglandin E receptor subtype is being considered, have anti-inflammatory, antipyretic and analgesic properties similar to a conventional non-steroidal anti-inflammatory drug, and in addition, inhibit hormone-induced uterine contractions and have anti-cancer effects. These compounds have a diminished ability to induce some of the mechanism-based side effects of NSAIDs which are indiscriminate cyclooxygenase inhibitors. In particular, the compounds have a reduced potential for gastrointestinal toxicity, a reduced potential for renal side effects, a reduced effect on bleeding times and a lessened ability to induce asthma attacks in aspirin-sensitive asthmatic subjects. Moreover, as a result of sparing potentially beneficial prostaglandin pathways, these agents may have enhanced efficacy over NSAIDs and/or COX-2 inhibitors. (See Pub. No. US 2005/0065200, for other diseases that may be treated by EP4 receptor antagonists.)

The TP (also known as TxA_2) receptor is a prostanoid receptor subtype stimulated by the endogenous mediator thromboxane. Activation of this receptor results in various physiological actions primarily incurred by its platelet aggregatory and smooth muscle constricting effects, thus opposing those of prostacyclin receptor activation.

TP receptors have been identified in human kidneys in the glomerulus and extraglomerular vascular tissue. Activation of TP receptors constricts glomerular capillaries and suppresses glomerular filtration rates indicating that TP receptor antagonists could be useful for renal dysfunction in glomerulonephritis, diabetes mellitus and sepsis.

Activation of TP receptors induces bronchoconstriction, an increase in microvascular permeability, formation of mucosal edema and mucus secretion, which are typical characteristic features of bronchial asthma. TP antagonists have been investigated as potential asthma treatments resulting in, for example, orally active Seratrodist (AA-2414). Ramatroban is another TP receptor antagonist currently undergoing phase III clinical trials as an anti-asthmatic compound.

Since the DP_1 receptor may trigger an asthmatic response in certain individuals, compounds that have DP_1 antagonist properties may be useful as anti-asthmatic drugs. (See Pub. No.

2004/0162323 for the disclosure of other diseases and conditions that may be treated with DP antagonists.)

Finally, the FP receptor modulates intraocular pressure and mediates smooth muscle contraction of the sphincter muscles in the gastrointestinal tract and the uterus. Thus, antagonists of the FP receptor are useful for treating reproductive disorders. (See US Patent No. 6,511,999 for other diseases and conditions that may be treated with FP receptor antagonists.)

As further background for the present invention, see US Published Patent Application 2007/0060596 .

BRIEF SUMMARY OF THE INVENTION

This invention provides a compound, that is a 1-[(5-halo or alkyl or fluoroalkyl or alkoxy-2-{{(hydrocarbyl or substituted hydrocarbyl)oxy}phenyl)methyl}-(3 and/or 5-alkyl or fluoroalkyl)-1H-pyrazole-4-(carboxylic acid or methylene carboxylic acid) or an alkyl or aryl ester or sulfonamide thereof.

In the compound of this invention said halo may be selected from the group consisting of chloro and bromo and said hydrocarbyl may be selected from the group consisting of alkyl and carbocyclic aryl.

Preferably, said hydrocarbyl is selected from the group consisting of branched chain alkyl and phenyl and more preferably said hydrocarbyl is selected from the group consisting of branched chain alkyl having from 4 to 7 carbons.

The compound of this invention may be a 1-[(5-chloro or bromo-or trifluoromethyl-2-{{hydrocarbyloxy}phenyl)methyl}-(3 and/or-5 methyl)-1H- pyrazole-4-carboxylic acid, wherein said hydrocarbyl is selected from the group consisting of alkyl and carbocyclic aryl and wherein said hydrocarbyl may be selected from the group consisting of branched chain alkyl and phenyl, e.g. a branched chain alkyl having from 4 to 7 carbons.

Most preferably, the compound of this invention is selected from the group consisting of:

1-[(5-Bromo-2-{2-ethylbutyloxy}phenyl)methyl]-5-methyl-1H-pyrazole-4-methylenecarboxylic acid;

1-[(5-Bromo-2-{2-ethylbutyloxy}phenyl)methyl]-5-methyl-1H-pyrazole-4-carboxylic acid;

5

1-[(5-Bromo-2-{2-ethylbutyloxy}phenyl)methyl]-3-methyl-1H-pyrazole-4-carboxylic acid;

1-[(5-chloro-2-{2-ethylbutyloxy}phenyl)methyl]-1H-pyrazole-4-carboxylic acid;

10 1-[(5-Chloro-2-{2-ethylbutyloxy}phenyl)methyl]-3,5-dimethyl-1H-pyrazole-4-carboxylic acid;

1-[(5-chloro-2-{2-ethylbutyloxy}phenyl)methyl]-3-propyl-1H-pyrazole-4-carboxylic acid;

15 1-[(5-chloro-2-{2-ethylbutyloxy}phenyl)methyl]-5-propyl-1H-pyrazole-4-carboxylic acid;

1-[(5-trifluoromethyl-2-{2-ethylbutyloxy}phenyl)methyl]-5-methyl-1H-pyrazole-4-carboxylic acid;

20 1-[(5-trifluoromethyl-2-{2-ethylbutyloxy}phenyl)methyl]-3-methyl-1H-pyrazole-4-carboxylic acid; and,

1-[(5-Chloro-2-{2-ethylbutyloxy}phenyl)methyl]-5-methyl-1H-pyrazole-4-carboxylic acid.

25 More preferably, the compound of this invention is selected from the group consisting of:

1-[(5-Bromo-2-{2-ethylbutyloxy}phenyl)methyl]-5-methyl-1H-pyrazole-4-methylenecarboxylic acid;

30 1-[(5-Bromo-2-{2-ethylbutyloxy}phenyl)methyl]-5-methyl-1H-pyrazole-4-carboxylic acid;

1-[(5-Bromo-2-{2-ethylbutyloxy}phenyl)methyl]-3-methyl-1H-pyrazole-4-carboxylic acid;

1-[(5-chloro-2-{2-ethylbutyloxy}phenyl)methyl]-1H-pyrazole-4-carboxylic acid;

1-[(5-Chloro-2-{2-ethylbutoxy}phenyl)methyl]-3,5-dimethyl-1H-pyrazole-4-carboxylic acid;

1-[(5-chloro-2-{2-ethylbutoxy}phenyl)methyl]-5-propyl-1H-pyrazole-4-carboxylic acid;

5

1-[(5-trifluoromethyl-2-{2-ethylbutoxy}phenyl)methyl]-5-methyl-1H-pyrazole-4-carboxylic acid;

1-[(5-Chloro-2-{2-ethylbutoxy}phenyl)methyl]-5-methyl-1H-pyrazole-4-carboxylic acid;

10 1-(5-chloro-2-isobutoxy-benzyl)-5-methyl-1h-pyrazole-4-carboxylic acid;

1-(5-chloro-2-cyclopentylmethoxy-benzyl)-5-methyl-1h-pyrazole-4-carboxylic acid;

1-(5-bromo-2-isobutoxy-benzyl)-5-methyl-1h-pyrazole-4-carboxylic acid;

15

1-[5-bromo-2-(2,2-dimethyl-propoxy) -benzyl]-5-methyl-1h-pyrazole-4-carboxylic acid;

1-[2-(2-ethyl-butoxy)-5-trifluoromethoxy-benzyl]-5-methyl-1h-pyrazole-4-carboxylic acid;
and,

20

5-amino-1-[5-bromo-2-(2-ethyl-butoxy)-benzyl]-1h-pyrazole-4-carboxylic acid.

Most preferably, said compound is:

25 1-[(5-Bromo-2-{2-ethylbutoxy}phenyl)methyl]-5-methyl-1H-pyrazole-4-methylenecarboxylic acid;

1-[(5-Bromo-2-{2-ethylbutoxy}phenyl)methyl]-5-methyl-1H-pyrazole-4-carboxylic acid;
or,

30

5-amino-1-[5-bromo-2-(2-ethyl-butoxy)-benzyl]-1h-pyrazole-4-carboxylic acid.

The invention further relates to pharmaceutical compositions containing the above compounds in combination with a pharmaceutically-acceptable excipient and to their use in

medicine, in particular their use in the treatment of conditions mediated by the action of ligands for the DP₁, FP, EP₁ and EP₄ prostaglandin (PG) receptors. The compounds of this invention are also useful for treating conditions mediated by the action of ligands for the thromboxane (TP) receptor.

5

Some embodiments of the present invention include:

1. A compound, that is a 1-[(5-halo or alkyl or fluoroalkyl or alkoxy-2-{(hydrocarbyl or substituted hydrocarbyl)oxy}phenyl)methyl]-(3 or 5 alkyl or fluoroalkyl)-1H-pyrazole-4-
10 (carboxylic acid or methylene carboxylic acid) or an alkyl or aryl ester or sulfonamide thereof. (As will be understood by those of ordinary skill in the art, certain compounds of the invention may be the same but have slightly different names. In one example, the compounds may be designated as a “methylene carboxylic acid” or an “acetic acid”. They are the same, despite the different nomenclature.).

15

2. The compound of paragraph 1 wherein said halo is selected from the group consisting of chloro and bromo.

3. The compound of paragraph 1 wherein said hydrocarbyl is selected from the group
20 consisting of alkyl and carbocyclic aryl.

4. The compound of paragraph 3 wherein said hydrocarbyl is selected from the group consisting of branched chain alkyl and phenyl.

25 5. The compound of paragraph 4 wherein said hydrocarbyl is selected from the group consisting of branched chain alkyl having from 4 to 7 carbons.

6. The compound of paragraph 1 wherein said compound is a 1-[(5-Chloro or bromo-or trifluoromethyl-2-{hydrocarbyloxy}phenyl)methyl]-(3 or 5 methyl)-1H- pyrazole-4-
30 carboxylic acid.

7. The compound of paragraph 6 wherein said hydrocarbyl is selected from the group consisting of alkyl and carbocyclic aryl.

8. The compound of paragraph 6 wherein said hydrocarbyl is selected from the group consisting of branched chain alkyl and phenyl.

9. The compound of paragraph 6 wherein said hydrocarbyl a branched chain alkyl
5 having from 4 to 7 carbons.

10. The compound of paragraph 1 that is selected from the group consisting of:

1-[(5-Bromo-2-{2-ethylbutyloxy}phenyl)methyl]-5-methyl-1H-pyrazole-4-
10 methylenecarboxylic acid;

1-[(5-Bromo-2-{2-ethylbutyloxy}phenyl)methyl]-5-methyl-1H-pyrazole-4-carboxylic acid;

1-[(5-Bromo-2-{2-ethylbutyloxy}phenyl)methyl]-3-methyl-1H-pyrazole-4-carboxylic acid;

1-[(5-chloro-2-{2-ethylbutyloxy}phenyl)methyl]-1H-pyrazole-4-carboxylic acid;

1-[(5-Chloro-2-{2-ethylbutyloxy}phenyl)methyl]-3,5-dimethyl-1H-pyrazole-4-carboxylic
acid;

1-[(5-chloro-2-{2-ethylbutyloxy}phenyl)methyl]-3-propyl-1H-pyrazole-4-carboxylic acid;


1-[(5-chloro-2-{2-ethylbutyloxy}phenyl)methyl]-5-propyl-1H-pyrazole-4-carboxylic acid;

1-[(5-trifluoromethyl-2-{2-ethylbutyloxy}phenyl)methyl]-5-methyl-1H-pyrazole-4-
25 carboxylic acid;

1-[(5-trifluoromethyl-2-{2-ethylbutyloxy}phenyl)methyl]-3-methyl-1H-pyrazole-4-
carboxylic acid; and,

1-[(5-Chloro-2-{2-ethylbutyloxy}phenyl)methyl]-5-methyl-1H-pyrazole-4-carboxylic acid.

11. A compound having the following formula:



5 X is O, NR₇ or (CH₂)_n, wherein n is 0 or an integer of 1 or 2;

Y is (CH₂)_m, wherein m is 0 or an integer of from 1 to 3;

10 Z is selected from the group consisting of O, S, SO, SO₂ and (CH₂)_p, wherein p is 0 or an integer of from 1 to 3;

W is hydrocarbyl or substituted hydrocarbyl;

15 R₁ is selected from the group consisting of OR₇, N(R₇)₂, and N(R₇)SO₂R₇;

R₂ is selected from the group consisting of H, hydroxy, alkyl, aryl, alkoxy, aryloxy, halogen, nitro, amino, cyano and hydroxy, halogen, nitro, amino and cyano-substituted alkyl, aryl, alkoxy or aryloxy;

20 R₄ is selected from the group consisting of H, NH₂, alkyl, nitrogen substituted alkyl and halogen-substituted alkyl;

25 R₅ is selected from the group consisting of H, hydroxy, alkyl, aryl, alkoxy, aryloxy, halogen, nitro, amino, cyano and hydroxy, halogen, nitro, amino and cyano-substituted alkyl, aryl, alkoxy or aryloxy;

R₆ is selected from the group consisting of H, hydroxy, alkyl, aryl, alkoxy, aryloxy, halogen, nitro, amino, cyano and hydroxy, halogen, nitro, amino and cyano-substituted alkyl, aryl, alkoxy or aryloxy; and,

- 5 R₇ is selected from the group consisting of H, hydrocarbyl and substituted hydrocarbyl, e.g. carbocyclic aryl and alkyl.

12. The compound of paragraph 11, wherein R₁ is OH.

- 10 13. The compound of paragraph 11, wherein R₂ is selected from the group consisting of H, alkyl and halogen-substituted alkyl, e.g. fluoro-substituted alkyl.

14. The compound of paragraph 11, wherein R₄ is selected from the group consisting of H, alkyl and halogen-substituted alkyl, e.g. fluoro-substituted alkyl.

15

15. The compound of paragraph 11, wherein R₁ is X is (CH₂)_n, wherein n is 0 or 1.

16. The compound of paragraph 11, wherein R₅ is selected from the group consisting of H, hydroxy, alkyl, aryl, alkoxy, aryloxy, halogen, nitro, amino, cyano and hydroxy, halogen,
20 nitro, amino and cyano-substituted alkyl, aryl, alkoxy or aryloxy.

17. The compound of paragraph 11, wherein R₅ is chloro or bromo.

18. The compound of paragraph 11, wherein R₆ is selected from the group consisting of
25 H, hydroxy, alkyl, aryl, alkoxy, aryloxy, halogen, nitro, amino, cyano and hydroxy, halogen, nitro, amino and cyano-substituted alkyl, aryl, alkoxy or aryloxy.

19. The compound of paragraph 18, wherein R₆ is H.

- 30 20. The compound of paragraph 11, wherein Y is absent, i.e. n is 0.

21. The compound of paragraph 11, wherein Z is O.

22. The compound of paragraph 11, wherein W is selected from the group consisting of alkyl, aryl, alkoxy, aryloxy and hydroxy, halogen, nitro, amino and cyano-substituted alkyl, aryl, alkoxy or aryloxy.

5 23. The compound of paragraph 22, wherein W is selected from the group consisting of alkyl, e.g. branched chain alkyl such as 2-ethylbutyl, 2-methylpropyl, etc. and carbocyclic aryl, e.g. phenyl.

24. The compound of paragraph 11 that is selected from the group consisting of:

10

1-[(5-Bromo-2-{2-ethylbutyloxy}phenyl)methyl]-5-methyl-1H-pyrazole-4-methylenecarboxylic acid;

1-[(5-Bromo-2-{2-ethylbutyloxy}phenyl)methyl]-5-methyl-1H-pyrazole-4-carboxylic acid;

15

and,

5-amino-1-[5-bromo-2-(2-ethyl-butoxy)-benzyl]-1h-pyrazole-4-carboxylic acid.

25. A method of making a {1-2-[(hydrocarbyl or substituted hydrocarbyloxy)-benzyl] 1H-pyrazol- or alkyl-1H-pyrazol)-4-yl }-acetic or carboxylic acid which comprises hydrolyzing the corresponding {1-2-[(hydrocarbyl or substituted hydrocarbyloxy)-benzyl]1H-pyrazol-4-yl}-acetic or carboxylic acid, alkyl ester to yield said {1-2-[(hydrocarbyl or substituted hydrocarbyloxy)-benzyl]1H-pyrazol-4-yl}-acetic or carboxylic acid.

20

25 26. The method of paragraph 25 wherein said {1-2-[(hydrocarbyl or substituted hydrocarbyloxy)-benzyl]1H-pyrazol-4-yl}-acetic or carboxylic acid is a {1-[halo or haloalkyl-2-(hydrocarbyloxy)-benzyl]-alkyl-1H-pyrazol-4-yl}-acetic or carboxylic acid.

27. The method of paragraph 26 wherein said {1-[halo or haloalkyl-2-(hydrocarbyloxy)-benzyl]-alkyl-1H-pyrazol-4-yl}-acetic or carboxylic acid is a {1-[5-halo or haloalkyl-2-(branched chain alkyl or phenyloxy)-benzyl]-3 and/or 5-alkyl-1H-pyrazol-4-yl}-acetic or carboxylic acid.

30

28. The method of paragraph 27 wherein said halo or haloalkyl is selected from the group consisting of chloro, bromo and trifluoromethyl.

29. The method of paragraph 27 wherein said hydrocarbyl is a branched chain alkyl
5 having from 4 to 7 carbons.

30. The method of paragraph 28 wherein said branched chain alkyl is 2-ethylbutyl.

31. The method of paragraph 27 wherein said 3 and/or 5 alkyl is selected from the group
10 consisting of methyl and n-propyl.

32. The method of paragraph 25 wherein said {1-2-[(hydrocarbyl or substituted hydrocarbyloxy)-benzyl] 1H-pyrazol- or alkyl-1H-pyrazol-4-yl }-acetic or carboxylic acid, alkyl ester is a {1-[5-bromo-2-(hydrocarbyloxy)-benzyl]-alkyl-1H-pyrazol-4-yl}-acetic or
15 carboxylic acid, alkyl ester and said method further comprises the step of reacting a solution of the corresponding[1-(5-Bromo-2-hydroxy-benzyl)alkyl-1H-pyrazol-4-yl]-acetic or carboxylic acid alkyl ester with the corresponding hydrocarbyl alcohol to obtain said {1-[2-(hydrocarbyl oxy)-benzyl]-alkyl-1H-pyrazol-4-yl}-acetic or carboxylic acid, alkyl ester.

33. The method of paragraph 31 wherein said {1-[2-(hydrocarbyl oxy)-benzyl] 1H-pyrazol- or alkyl-1H-pyrazol-4-yl}-acetic or carboxylic acid, alkyl ester is a [1-(5-Bromo-2-hydroxy-benzyl)-5-methyl-1H-pyrazol-4-yl]-carboxylic or acetic acid ethyl ester and said
20 method further comprises the steps of reacting a suspension of N'-(5-bromo-2-hydroxy-benzyl)-hydrazinecarboxylic acid tert-butyl ester with a mixture of CH₂Cl₂ and TFA and
25 removing the

volatiles therefrom to obtain a residue, dissolving said residue in absolute EtOH and adding a 3-[1-dimethylamino-methylidene]-oxoalkanoic acid ethyl ester to the resulting solution and obtaining a [1-(5-Bromo-2-hydroxy-benzyl)-5-methyl-1H-pyrazol-4-yl]-carboxylic or acetic
30 acid ethyl ester.

34. The method of paragraph 32 wherein said 3-[1-dimethylamino-methylidene]-oxoalkanoic acid ethyl ester is 3-[1-dimethylamino-methylidene]-4-oxo-pentanoic acid ethyl ester to yield the acetic acid ethyl ester.

5 35. The method of paragraph 32 wherein said 3-[1-dimethylamino-methylidene]-oxoalkanoic acid ethyl ester is 2-[1-Dimethylamino-meth-(Z)-ylidene]-3-oxo-butyric acid methyl ester to yield the carboxylic acid ethyl ester.

36. The method of paragraph 25 wherein said {1-2-[(hydrocarbyl or substituted hydrocarbyloxy)-benzyl] 1H-pyrazol- or alkyl-1H-pyrazol-4-yl }-acetic or carboxylic acid, alkyl ester is a {1-[5-chloro-2-(hydrocarbyloxy)-benzyl]-(1H-pyrazol- or alkyl-1H-pyrazol)-4-yl}-acetic or carboxylic acid, alkyl ester and said method further comprises the steps of reacting a solution of a 4-pyrazole or an alkyl-4-pyrazole carboxylate with NaH, under an inert atmosphere, e.g. a N₂ atmosphere, contacting the resulting reaction product with a solution of methanesulfonic acid 5-chloro-2-(hydrocarbyloxy)-benzyl ester in a polar aprotic solvent, e.g. DMF, to obtain a 1-[5-Chloro-2-(hydrocarbyloxy)-benzyl]- (1H-pyrazol- or alkyl-1H-pyrazol) -4-acetic or carboxylic acid alkyl ester.

37. The method of paragraph 35 wherein said method further comprises the step of reacting a solution of [5-Chloro-2-(hydrocarbyloxy)-phenyl]-methanol, di-isopropyl-ethyl amine and methanesulfonic anhydride in CH₂Cl₂ to obtain said methanesulfonic acid 5-chloro-2-(hydrocarbyloxy)-benzyl ester.

38. The method of paragraph 36 wherein said method further comprises the step of reacting a solution of 5-Chloro-2-(hydrocarbyloxy)-benzaldehyde, MeOH and NaBH₄ under an inert atmosphere, e.g. N₂, to obtain said [5-Chloro-2-(hydrocarbyloxy)-phenyl]-methanol.

39. The method of paragraph 38 wherein said method further comprises the step of reacting a solution of 5-chloro-2-hydroxybenzaldehyde in a polar aprotic solvent, e.g. DMF, under an inert atmosphere, e.g. a N₂ atmosphere, at RT with 3-(chloromethyl)pentane, K₂CO₃, and tetrabutylammonium iodide to obtain 5-Chloro-2-(hydrocarbyloxy)-benzaldehyde.

40. The method of paragraph 35 wherein said pyrazol-4-yl is a 3 and/or 5 alkyl pyrazol-4-yl, e.g. a methyl or propyl pyrazol-4-yl.


41. The method of paragraph 25 wherein said {1-2-[(hydrocarbyl or substituted
5 hydrocarbyloxy)-benzyl] 1H-pyrazol- or alkyl-1H-pyrazol-4-yl }-acetic or carboxylic acid, alkyl ester is a {1-[5-trifluoromethyl-2-(hydrocarbyloxy)-benzyl]-alkyl-1H-pyrazol-4-yl}-acetic or carboxylic acid, alkyl ester and said method further comprises the step of reacting a solution of the corresponding[1-(5- trifluoromethyl -2-hydroxy-benzyl)alkyl-1H-pyrazol-4-yl]-acetic or carboxylic acid alkyl ester with the corresponding hydrocarbyl alcohol to obtain
10 said {1-[5- trifluoromethyl-2-(hydrocarbyl oxy)-benzyl]-alkyl-1H-pyrazol-4-yl}-acetic or carboxylic acid, alkyl ester.

42. The method of paragraph 41 further comprising the steps of providing a solution of 1-(5-Methoxy-2-trifluoromethyl-benzyl)-5-methyl-1H-pyrazole-4-carboxylic acid ethyl ester in
15 dry DCM, at 0° C, under an inert atmosphere, e.g. a N₂ atmosphere, a boron tribromide allowing the solution to warm to room temperature, quenching the solution with MeOH and refluxing to yield 1-(5-Trifluoromethyl-2-hydroxy-benzyl)- methyl-1H-pyrazol-4-yl carboxylic acid methyl ester.

20 43. The method of paragraph 42 further comprising the steps of providing a solution of ethyl-4-pyrazole carboxylate in a polar aprotic solvent, e.g. DMF, under an inert atmosphere, e.g. a N₂

atmosphere, at RT, and sequentially adding to said solution, NaH in mineral oil and a solution
25 of bromomethylsubstituted benzyl5-chloro-2-(2-ethyl-butoxy)-benzyl ester in a polar aprotic solvent, e.g. DMF, pouring the resulting solution into water, removing the volatiles and purifying the resulting crude product to yield 1-[5-Trifluoromethyl-2-(2-ethyl-butoxy)-benzyl]-1H-pyrazole-4-carboxylic acid ethyl ester as a 3:2 mixture with its regioisomer.

30 44. A method comprising administering a compound having the following formula:



Wherein X is O, NR₇ or (CH₂)_n, wherein n is 0 or an integer of 1 or 2;

5 Y is (CH₂)_m, wherein m is 0 or an integer of from 1 to 3;

Z is selected from the group consisting of O, S, SO, SO₂ and (CH₂)_p, wherein p is 0 or an integer of from 1 to 3;

10 W is hydrocarbyl or substituted hydrocarbyl;

R₁ is selected from the group consisting of OR₇, N(R₇)₂, and N(R₇)SO₂R₇;

R₂ is selected from the group consisting of H, hydroxy, alkyl, aryl, alkoxy, aryloxy, halogen,
 15 nitro, amino, cyano and hydroxy, halogen, nitro, amino and cyano-substituted alkyl, aryl, alkoxy or aryloxy;

R₄ is selected from the group consisting of H, NH₂, alkyl, nitrogen-substituted alkyl and halogen-substituted alkyl;

20

R₅ is selected from the group consisting of H, hydroxy, alkyl, aryl, alkoxy, aryloxy, halogen, nitro, amino, cyano and hydroxy, halogen, nitro, amino and cyano-substituted alkyl, aryl, alkoxy or aryloxy;

R₆ is selected from the group consisting of H, hydroxy, alkyl, aryl, alkoxy, aryloxy, halogen,
 25 nitro, amino, cyano and hydroxy, halogen, nitro, amino and cyano-substituted alkyl, aryl, alkoxy or aryloxy; and,

R₇ is selected from the group consisting of H, hydrocarbyl and substituted hydrocarbyl, e.g. carbocyclic aryl and alkyl.

45. The method of paragraph 44 wherein said compound is administered to treat DP1, FP,
5 EP1, TP and/or EP4 receptor mediated diseases or conditions.

46. The method of paragraph 45 wherein said condition or disease is related to inflammation.

10 47. The method of paragraph 45 wherein said DP1, FP, EP1, TP and/or EP4 receptor mediated condition or disease is selected from the group consisting of allergic conditions, asthma, allergic asthma, allergic rhinitis, uveitis and related disorders, atherosclerosis, blood coagulation disorders, bone disorders, cancer, cellular neoplastic transformations, chronic obstructive pulmonary diseases and other forms of lung inflammation, congestive heart
15 failure, diabetic retinopathy, diseases or conditions requiring a treatment of anti-coagulation, diseases requiring control of bone formation and resorption, fertility disorders, gangrene, glaucoma, hyperpyrexia, immune and autoimmune diseases, inflammatory conditions, metastatic tumor growth, migraine, mucus secretion disorders, nasal congestion, nasal inflammation, occlusive vascular diseases, ocular hypertension, ocular hypotension,
20 osteoporosis, rheumatoid arthritis, pain, perennial rhinitis, pulmonary congestion, pulmonary hypotension, Raynaud's disease, rejection in organ transplant and by-pass surgery, respiratory conditions, hirsutism, rhinorrhea, shock, sleep disorders, and sleep-wake cycle disorders.

48. The method of paragraph 45 wherein said compound is administered as a surgical
25 adjunct in ophthalmology for cataract removal and artificial lens insertion, ocular implant procedures, photorefractive radial keratotomy and other ophthalmological laser procedures.

49. The method of paragraph 45 wherein said compound is administered as a surgical adjunct in a procedure involving skin incisions, relief of pain and inflammation and scar
30 formation/keloids post-surgery, for treating sports injuries and general aches and pains in muscles and joints.

50. The method of paragraph 45 wherein said DP₁, FP, EP₁, TP, and/or EP₄ receptor mediated condition or disease is an EP₁ and/or EP₄ receptor mediated condition or disease.

51. The method of paragraph 42 wherein said DP₁, FP, EP₁, TP and/or EP₄ receptor mediated condition or disease is an allergic condition.

52. The method of paragraph 51 wherein said condition is dermatological allergy.

53. The method of paragraph 51 wherein said condition is an ocular allergy.

54. The method of paragraph 51 wherein said condition is a respiratory allergy.

55. The method of paragraph 45 wherein said condition or disease is selected from the group consisting of nasal congestion, rhinitis, and asthma.

56. The method of paragraph 45 wherein said condition or disease is related to pain.

57. The method of paragraph 45 wherein said condition or disease is selected from the group consisting of arthritis, migraine, and headache.

58. The method of paragraph 45 wherein said condition or disease is associated with the gastrointestinal tract.

59. The method of paragraph 45 wherein said condition or disease is selected from the group consisting of peptic ulcer, heartburn, reflux esophagitis, erosive esophagitis, non-ulcer dyspepsia, infection by *Helicobacter pylori*, alrnyitis, and irritable bowel syndrome.

60. The method of paragraph 56 wherein said condition or disease is selected from the group consisting of hyperalgesia and allodynia.

61. The method of paragraph 45 wherein said condition or disease is related to mucus secretion.

62. The method of paragraph 45 wherein said mucus secretion is gastrointestinal.

63. The method of paragraph 45 wherein said mucus secretion occurs in the nose, sinuses, throat, or lungs.

5

64. The method of paragraph 45 wherein said condition or disease is related to abdominal cramping.

10

65. The method of paragraph 45 wherein said condition or disease is irritable bowel syndrome.

66. The method of paragraph 45 wherein said condition or disease is a bleeding disorder.

15

67. The method of paragraph 45 wherein said condition or disease is a sleep disorder.

68. The method of paragraph 45 wherein said condition or disease is mastocytosis.

69. The method of paragraph 45 wherein said condition or disease is associated with elevated body temperature.

20

70. The method of paragraph 45 wherein said condition or disease is associated with ocular hypertension and glaucoma.

25


71. The method of paragraph 45 wherein said condition or disease is associated with ocular hypotension.

72. The method of paragraph 45 wherein said condition relates to surgical procedure to treat pain, inflammation and other unwanted sequelae wherein said surgical procedure includes incision, laser surgery or implantation.

30

73. The method of paragraph 45 where said condition is related to pain and inflammation and post-surgical scar and keloid formation.

74. A pharmaceutical product comprising a compound having the following formula:



5

Wherein X is O, NR₇ or (CH₂)_n, wherein n is 0 or an integer of 1 or 2;

Y is (CH₂)_m, wherein m is 0 or an integer of from 1 to 3;

10 Z is selected from the group consisting of O, S, SO, SO₂ and (CH₂)_p, wherein p is 0 or an integer of from 1 to 3;

W is hydrocarbyl or substituted hydrocarbyl;

15 R₁ is selected from the group consisting of OR₇, N(R₇)₂, and N(R₇)SO₂R₇;

R₂ is selected from the group consisting of H, hydroxy, alkyl, aryl, alkoxy, aryloxy, halogen, nitro, amino, cyano and hydroxy, halogen, nitro, amino and cyano-substituted alkyl, aryl, alkoxy or aryloxy;

20

R₄ is selected from the group consisting of H, NH₂, alkyl, nitrogen-substituted alkyl and halogen-substituted alkyl;


R₅ is selected from the group consisting of H, hydroxy, alkyl, aryl, alkoxy, aryloxy, halogen, nitro, amino, cyano and hydroxy, halogen, nitro, amino and cyano-substituted alkyl, aryl, alkoxy or aryloxy;

25

R_6 is selected from the group consisting of H, hydroxy, alkyl, aryl, alkoxy, aryloxy, halogen, nitro, amino, cyano and hydroxy, halogen, nitro, amino and cyano-substituted alkyl, aryl, alkoxy or aryloxy; and,

- 5 R_7 is selected from the group consisting of H, hydrocarbyl and substituted hydrocarbyl, e.g. carbocyclic aryl and alkyl or a pharmaceutically acceptable salt or a prodrug thereof, wherein said product is packaged and labeled for the treatment or prevention of a disease or condition selected from the group consisting of uveitis, allergic conditions, asthma, allergic asthma, allergic rhinitis, atherosclerosis, blood coagulation disorders, bone disorders, cancer, cellular
- 10 neoplastic transformations, chronic obstructive pulmonary diseases and other forms of lung inflammation, congestive heart failure, diabetic retinopathy, diseases or conditions requiring a treatment of anti-coagulation, diseases requiring control of bone formation and resorption, fertility disorders, hyperpyrexia, gangrene, glaucoma, hypothermia, immune and autoimmune diseases, inflammatory conditions, metastatic tumor growth, migraine, mucus
- 15 secretion disorders, nasal congestion, nasal inflammation, occlusive vascular diseases, ocular hypertension, ocular hypotension, osteoporosis, pain, perennial rhinitis, pulmonary congestion, pulmonary hypotension, Raynaud's disease, rejection in organ transplant and bypass surgery, respiratory conditions, rheumatoid arthritis, rhinorrhea, shock, sleep disorders, sleep-wake cycle disorders, sports injuries, muscle aches and pains, and surgical adjunct for
- 20 minimizing pain, inflammation and scar/keloid formation.

75. A pharmaceutical composition comprising a compound having the following formula:



- 25 wherein X is O, NR_7 or $(CH_2)_n$, wherein n is 0 or an integer of 1 or 2;

Y is $(CH_2)_m$, wherein m is 0 or an integer of from 1 to 3;

Z is selected from the group consisting of O, S, SO, SO₂ and (CH₂)_p, wherein p is 0 or an integer of from 1 to 3;

W is hydrocarbyl or substituted hydrocarbyl;

5

R₁ is selected from the group consisting of OR₇, N(R₇)₂, and N(R₇)SO₂R₇;

R₂ is selected from the group consisting of H, hydroxy, alkyl, aryl, alkoxy, aryloxy, halogen, nitro, amino, cyano and hydroxy, halogen, nitro, amino and cyano-substituted alkyl, aryl, alkoxy or aryloxy;

10

R₄ is selected from the group consisting of H, NH₂, alkyl, nitrogen-substituted alkyl and halogen-substituted alkyl;

R₅ is selected from the group consisting of H, hydroxy, alkyl, aryl, alkoxy, aryloxy, halogen, nitro, amino, cyano and hydroxy, halogen, nitro, amino and cyano-substituted alkyl, aryl, alkoxy or aryloxy;

15

R₆ is selected from the group consisting of H, hydroxy, alkyl, aryl, alkoxy, aryloxy, halogen, nitro, amino, cyano and hydroxy, halogen, nitro, amino and cyano-substituted alkyl, aryl, alkoxy or aryloxy; and,

20

R₇ is selected from the group consisting of H, hydrocarbyl and substituted hydrocarbyl, e.g. carbocyclic aryl and alkyl or a pharmaceutically acceptable salt or a prodrug thereof, and a pharmaceutically acceptable excipient.

25

BRIEF DESCRIPTION OF THE DRAWING FIGURES

Figures 1, 2 and 3 show the reaction schemes for the preparation of the compounds of this invention.

30

DETAILED DESCRIPTION OF THE INVENTION

The following terms are used to define the disclosed invention.

“Hydrocarbyl” refers to a hydrocarbon radical having only carbon and hydrogen atoms.

5 Preferably, the hydrocarbyl radical has from 1 to 20 carbon atoms, more preferably from 1 to 12 carbon atoms and most preferably from 1 to 7 carbon atoms.

10 “Substituted hydrocarbyl” refers to a hydrocarbyl radical wherein one or more, but not all, of the hydrogen and/or the carbon atoms are replaced by a halogen, nitrogen, oxygen, sulfur or phosphorus atom or a radical including a halogen, nitrogen, oxygen, sulfur or phosphorus atom, e.g. fluoro, chloro, cyano, nitro, hydroxyl, phosphate, thiol, etc.

15 “Methylenyl” refers to a $-\text{CH}_2-$ linking group. “Alkyl” refers to a straight-chain, branched or cyclic saturated aliphatic hydrocarbon. Preferably, the alkyl group has 1 to 12 carbons. More preferably, it is an alkyl of from 4 to 10 carbons, most preferably 4 to 8 carbons. Typical alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tertiary butyl, pentyl, hexyl and the like. The alkyl group may be optionally substituted with one or more substituents are selected from the group consisting of hydroxyl, cyano, alkoxy, $=\text{O}$, $=\text{S}$, NO_2 , halogen, dimethyl amino, and SH.

20

"Cycloalkyl" refers to a cyclic saturated aliphatic hydrocarbon group. Preferably, the cycloalkyl group has 3 to 12 carbons. More preferably, it has from 4 to 7 carbons, most preferably 5 or 6 carbons.

25 "Aryl" refers to an aromatic group which has at least one ring having a conjugated pi electron system and includes carbocyclic aryl, heterocyclic aryl and biaryl groups. The aryl group may be optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxyl, halogen, COOR^7 , NO_2 , CF_3 , $\text{N}(\text{R}^7)_2$, $\text{CON}(\text{R}^7)_2$, SR^7 , sulfoxy, sulfone, CN and OR^7 , wherein R^7 is selected from the group consisting of H, hydrocarbyl and substituted hydrocarbyl, e.g. carbocyclic aryl and alkyl

30


“Carbocyclic aryl” refers to an aryl group wherein the ring atoms are carbon.

"Heteroaryl or heterocyclic aryl" refers to an aryl group having from 1 to 3 heteroatoms as ring atoms, the remainder of the ring atoms being carbon. Heteroatoms include oxygen, sulfur, and nitrogen. Thus, heterocyclic aryl groups include furanyl, thienyl, pyridyl, pyrrolyl, N-lower alkyl pyrrolo, pyrimidyl, pyrazinyl, imidazolyl and the like. Preferably, the heteroaryl group has from 2 to 10 carbons. More preferably, it has from 3 to 10 carbons, most preferably 3 carbons.

Pharmaceutical compositions contemplated herein include compositions wherein the active ingredient is contained in an effective amount, i.e., in an amount effective to achieve its intended purpose. An "effective amount" is an amount sufficient to accomplish a stated purpose (e.g., achieve the effect for which it is administered, treat a disease, reduce one or more symptoms of a disease or condition). An example of an "effective amount" is an amount sufficient to contribute to the treatment, prevention, or reduction of a symptom or symptoms of a disease, which can be referred to as a "therapeutically effective amount." A "reduction" of a symptom or symptoms (and grammatical equivalents of this phrase) means decreasing of the severity or frequency of the symptom(s), or elimination of the symptom(s). The actual amount effective for a particular application will depend, *inter alia*, on the condition being treated.

"Treatment", "treat" or "treating" can refer to curing any disease or condition or reducing or alleviating the symptoms of the disease or condition.

The present invention provides compounds having the general formula:



Wherein X is O, NR₇ or (CH₂)_n, wherein n is 0 or an integer of 1 or 2;

Y is (CH₂)_m, wherein m is 0 or an integer of from 1 to 3;

- 5 Z is selected from the group consisting of O, S, SO, SO₂ and (CH₂)_p, wherein p is 0 or an integer of from 1 to 3;

W is hydrocarbyl or substituted hydrocarbyl;

- 10 R₁ is selected from the group consisting of OR₇, N(R₇)₂, and N(R₇)SO₂R₇;

R₂ is selected from the group consisting of H, hydroxy, alkyl, aryl, alkoxy, aryloxy, halogen, nitro, amino, cyano and hydroxy, halogen, nitro, amino and cyano-substituted alkyl, aryl, alkoxy or aryloxy;

15

R₄ is selected from the group consisting of H, NH₂, alkyl, nitrogen-substituted alkyl and halogen-substituted alkyl;

- 20 R₅ is selected from the group consisting of H, hydroxy, alkyl, aryl, alkoxy, aryloxy, halogen, nitro, amino, cyano and hydroxy, halogen, nitro, amino and cyano-substituted alkyl, aryl, alkoxy or aryloxy;

- 25 R₆ is selected from the group consisting of H, hydroxy, alkyl, aryl, alkoxy, aryloxy, halogen, nitro, amino, cyano and hydroxy, halogen, nitro, amino and cyano-substituted alkyl, aryl, alkoxy or aryloxy;

R₇ is selected from the group consisting of H, hydrocarbyl and substituted hydrocarbyl, e.g. carbocyclic aryl and alkyl;

- 30 Preferably, R₁ is OH;

Preferably, R₂ is selected from the group consisting of H, alkyl and halogen-substituted alkyl, e.g. fluoro-substituted alkyl;

Preferably, R₄ is selected from the group consisting of H, alkyl and halogen-substituted alkyl, e.g. fluoro-substituted alkyl;

Preferably, X is (CH₂)_n, wherein n is 0 or 1;

5

Preferably, R₅ is selected from the group consisting of H, hydroxy, alkyl, aryl, alkoxy, aryloxy, halogen, nitro, amino, cyano and hydroxy, halogen, nitro, amino and cyano-substituted alkyl, aryl, alkoxy or aryloxy. More preferably R₅ is chloro or bromo;

10

Preferably, R₆ is selected from the group consisting of H, hydroxy, alkyl, aryl, alkoxy, aryloxy, halogen, nitro, amino, cyano and hydroxy, halogen, nitro, amino and cyano-substituted alkyl, aryl, alkoxy or aryloxy. More preferably R₆ is H;

Preferably, Y is absent, i.e. n is 0;

15

Preferably, Z is O;

Preferably, W is selected from the group consisting of alkyl, aryl, alkoxy, aryloxy and hydroxy, halogen, nitro, amino and cyano-substituted alkyl, aryl, alkoxy or aryloxy.

20

More preferably, W is selected from the group consisting of alkyl, e.g. branched chain alkyl such as 2-ethylbutyl, 2-methylpropyl, etc. and carbocyclic aryl, e.g. phenyl.

As shown in the Examples, below, preferably, certain of the preferred compounds of the present invention are prepared by a method of making a 1-[(hydrocarbyloxy)-benzyl]-1H-pyrazole-4-carboxylic acid which comprises the steps of:

25

(1) adding a reducing agent, e.g. NaH in mineral oil, to a solution of alkyl-4-pyrazole carboxylate dissolved in a polar aprotic solvent, e.g. DMF, under an inert atmosphere and stirring at RT;

30

(2) adding to the resulting mixture of step(1), a solution of methanesulfonic acid 2-(hydrocarbyl)-benzyl ester in a polar aprotic solvent, e.g. DMF, and stirring the resulting

mixture for a sufficient time, e.g. 16 hours, to yield a reaction product comprising a 1-[2-(hydrocarbyl)-benzyl]-1H-pyrazole-4-carboxylic acid alkyl ester; and,

- (3) hydrolyzing the reaction product of step(2) comprising said 1-[2-(hydrocarbyl)-benzyl]-1H-pyrazole-4-carboxylic acid alkyl ester; and recovering a 1-[2-(hydrocarbyl)-benzyl]-1H-pyrazole-4-carboxylic acid.

An example of the above preferred method of making the preferred compounds, as shown in Example 4, below, is a method of making 1-[5-chloro-2-(2-ethyl-butoxy)-benzyl]-1H-pyrazole-4-carboxylic acid which comprises the steps of:

- (1) adding NaH in mineral oil to a solution of ethyl-4-pyrazole carboxylate dissolved in a polar aprotic solvent under an inert atmosphere at RT and stirring;
- (2) adding to the resulting mixture of step(1), a solution of methanesulfonic acid 5-chloro-2-(2-ethyl-butoxy)-benzyl ester dissolved in a polar aprotic solvent and stirring the resulting mixture at conditions sufficient to yield 1-[5-Chloro-2-(2-ethyl-butoxy)-benzyl]-1H-pyrazole-4-carboxylic acid ethyl ester;
- (3) hydrolyzing the reaction product of step(2) to obtain 1-[5-chloro-2-(2-ethyl-butoxy)-benzyl]-1H-pyrazole-4-carboxylic acid; and,
- (4) recovering 1-[2-(hydrocarbyl)-benzyl]-1H-pyrazole-4-carboxylic acid.
- Said 5-chloro-2-(2-ethyl-butoxy)-phenyl]-methanol may be obtained by cooling a solution of 5-Chloro-2-(2-ethyl-butoxy)-benzaldehyde in MeOH to +5 °C under an inert atmosphere and adding NaBH and allowing the resulting mixture to warm to RT over 2 hours.

Said 5-Chloro-2-(2-ethyl-butoxy)-benzaldehyde, 10 may be obtained by adding a solution of 3-(chloromethyl)pentane, K₂CO and tetrabutylammonium iodide in a polar aprotic solvent to a solution of 5-chloro-2-hydroxybenzaldehyde in a polar aprotic solvent under an inert atmosphere at RT and stirring the resulting mixture at 120° C for a time sufficient to obtain a reaction product comprising 5-Chloro-2-(2-ethyl-butoxy)-benzaldehyde.

Methanesulfonic acid 5-chloro-2-(2-ethyl-butoxy)-benzyl ester may be obtained by reacting a solution of [5-Chloro-2-(2-ethyl-butoxy)-phenyl]-methanol **11**, di-isopropyl-ethyl amine and methanesulfonic anhydride under an inert atmosphere at conditions sufficient to yield said methanesulfonic acid 5-chloro-2-(2-ethyl-butoxy)-benzyl ester.

5

The corresponding bromo compound is prepared in Example 2 by an analogous method.

Said polar aprotic solvent may be selected from the group consisting of dichloromethane, tetrahydrofuran, ethylacetate, acetone, dimethylformamide, and acetonitrile.

10

The following examples are intended to illustrate the present invention.

The reagents and conditions used in Figures 1, 2, 3 and the Examples may be abbreviated as follows:

15

Ac is acetyl;

DCM is dichloromethane;

20

RT is room temperature;

Ph is phenyl;

DMF is dimethylformamide;

25

Et is ethyl;


THF is tetrahydrofuran; and,

30

HEPES is 4- (2-hydroxyethyl)-1-piperazineethanesulfonic acid).

EXAMPLE 1


**{1-[5-BROMO-2-(2-ETHYL-BUTOXY)-BENZYL]-5-METHYL-1H-PYRAZOL-4-YL}-
ACETIC ACID, 4.**



5

STEP 1

N'-(5-bromo-2-hydroxy-benzyl)-hydrazinecarboxylic acid tert-butyl ester 1



10

A solution of 5-bromo-2-hydroxybenzaldehyde (10g g 50 mmol), tert-butylcarbazate(6.7 g, 52 mmol) and acetic acid (3 mL, 52 mmol) in CH₂Cl₂ (200 mL) was stirred under N₂ atmosphere for 60 min at RT. Then sodium triacetoxymorohydride (34 g, 159 mmol) was added portion wise

15 and the resulting mixture was stirred at RT overnight. The reaction was quenched with 2 M HCl (100 mL) and stirred at RT for 1 h. The reaction mixture was partitioned between water (100 mL) and CH₂Cl₂ (250 mL). The organic layer was washed with sat. NaHCO₃ and brine (100 mL each), dried (MgSO₄) and evaporated to dryness to give hydrazine 1 as a white solid, 13 g (82 %).


$^1\text{H-NMR}(\text{CDCl}_3, 300 \text{ MHz}) \delta 7.29 (\text{dd}, \text{H ArH}, J = 2.4, 8.6 \text{ Hz}), 7.17 (\text{d}, 1\text{H}, J = 2.4 \text{ Hz}, \text{ArH}), 6.80 (\text{d}, 1\text{H}, J = 8.6 \text{ Hz}, \text{ArH}), 1.49 (\text{s}, 9\text{H}, -\text{C}(\text{CH}_3)_3).$

LC-MS: m/z 318 $\text{M} + \text{H}^+$

5

STEP 2

[1-(5-Bromo-2-hydroxy-benzyl)-5-methyl-1H-pyrazol-4-yl]-acetic acid ethyl ester, 2.



- 10 A suspension of N'-(5-bromo-2-hydroxy-benzyl)-hydrazinecarboxylic acid tert-butyl ester 1 g (3.1 mmol) in a mixture of CH_2Cl_2 (8 mL) and TFA (8 mL) was stirred at RT for 2 hours. The volatiles were removed *in vacuo*. The residue was dissolved in abs. EtOH (7 mL) and added to 3-[1-dimethylamino-methylidene]-4-oxo-pentanoic acid ethyl ester (4.8 mmol) at RT. The resulting mixture was stirred at RT for 1 hour, refluxed for 2 h, let cool down and
- 15 stirred at RT for 16 h. The oily residue obtained after removing the volatiles *in vacuo* was purified by MPLC (10 g SiO_2 cartridge, eluent 90 % iso-hexane – 10 % EtOAc) to give 0.18g of [1-(5-Bromo-2-hydroxy-benzyl)-5-methyl-1H-pyrazol-4-yl]-acetic acid ethyl ester, 2.


$^1\text{H-NMR}(\text{CDCl}_3, 300 \text{ MHz}) \delta 7.45 (\text{s}, 1\text{H}, \text{ArH}), 7.33 (\text{dd}, 1\text{H}, \text{ArH}), 7.27 (\text{dd}, 1\text{H}, \text{ArH}), 6.87 (\text{dd}, 1\text{H}, \text{ArH}), 5.11 (\text{s}, 2\text{H}, \text{ArCH}_2), 4.16 (\text{q}, 2\text{H}, -\text{CH}_2\text{CH}_3), 3.39 (\text{s}, 2\text{H}, \text{ArCH}_2), 2.34 (\text{s}, 3\text{H}, \text{CH}_3), 1.27 (\text{t}, 3\text{H}, -\text{CH}_2\text{CH}_3).$

LC-MS: m/z 354 $\text{M} + \text{H}^+$

20

STEP 3

{1-[5-Bromo-2-(2-ethyl-butoxy)-benzyl]-5-methyl-1H-pyrazol-4-yl}-acetic acid ethyl ester, 3.



5

A solution of [1-(5-Bromo-2-hydroxy-benzyl)-5-methyl-1H-pyrazol-4-yl]-acetic acid ethyl ester, **2**, (0.18g g 0.51 mmol), triphenylphosphine (0.26g, 1.02 mmol), di-tert-butylazodicarboxylate (0.23g, 1.02 mmol) and 2-ethylbutan-1-ol (0.116 ml, 1.02 mmol) in a mixture of THF (1 mL) and toluene (2ml) was at 120 °C on microwave for 20 min. The
 10 volatiles were removed *in vacuo*. The crude product was purified on silica to yield {1-[5-bromo-2-(2-ethyl-butoxy)-benzyl]-5-methyl-1H-pyrazol-4-yl}-acetic acid ethyl ester, **3**, a pale yellow oil, 0.1g (45 %).


¹H-NMR(CDCl₃, 300 MHz) δ 7.49 (s, 1H, ArH), 7.32 (dd, 1H, ArH), 6.76 (d, 1H, ArH),
 15 6.65 (dd, 1H, ArH), 5.27 (s, 2H, ArCH₂), 4.17 (q, 2H, -CH₂CH₃), 3.90 (dd, 2H, CH₂), 3.45 (s, 2H, ArCH₂), 2.16 (s, 3H, CH₃), 1.71 (m, 1H, CH), 1.50 (m, 4H, CH₂), 1.28 (t, 3H, -CH₂CH₃), 0.96 (t, 6H, CH₃).

LC-MS: m/z 438 M + H⁺

20

STEP 4


{1-[5-Bromo-2-(2-ethyl-butoxy)-benzyl]-5-methyl-1H-pyrazol-4-yl}-acetic acid, 4.




- 5 To a solution of {1-[5-bromo-2-(2-ethyl-butoxy)-benzyl]-5-methyl-1H-pyrazol-4-yl}-acetic acid ethyl ester, **3**, 0.1g (0.22 mmol) in a mixture of THF (1 mL) and methanol (0.5 ml) was added a solution of LiOH (0.12g in 1 ml H₂O). The resulting mixture was heated at 100 °C on microwave for 20 minutes. The mixture was poured into water (20 mL) and extracted with EtOAc (3 x 15 mL). The organic layers were combined, washed with brine (30 mL), dried
- 10 (MgSO₄) and the volatiles removed *in vacuo*. The crude product was purified on silica to yield 7.4 mg (10%) of {1-[5-Bromo-2-(2-ethyl-butoxy)-benzyl]-5-methyl-1H-pyrazol-4-yl}-acetic acid, **4** as a white solid.

¹H-NMR (CDCl₃, 300 MHz) δ 7.50 (s, 1H, ArH), 7.32 (dd, 1H, ArH), 6.76 (d, 1H, ArH), 6.70 (dd, 1H, ArH), 5.27 (s, 2H, ArCH₂), 3.90 (dd, 2H, CH₂), 3.50 (s, 2H, ArCH₂), 2.16 (s, 3H, CH₃), 1.70 (m, 1H, CH), 1.50 (m, 4H, CH₂), 0.96 (t, 6H, CH₃).

LC-MS: m/z 410 M + H⁺

EXAMPLE 2**1-[5-BROMO-2-(2-ETHYL-BUTOXY)-BENZYL]-5-METHYL-1H-PYRAZOLE-4-CARBOXYLIC ACID, 7.**

5

STEP 1**1-(5-Bromo-2-hydroxy-benzyl)-5-methyl-1H-pyrazole-4-carboxylic acid methyl ester, 5.**


A suspension of N'-(5-bromo-2-hydroxy-benzyl)-hydrazinecarboxylic acid tert-butyl ester 1
2g (6.3 mmol) in a mixture of CH₂Cl₂ (8 mL) and TFA (8 mL) was stirred at RT for 2 hours.

10 The volatiles were removed *in vacuo*. The residue was dissolved in abs. EtOH (7 mL) and
added to 2-[1-Dimethylamino-meth-(Z)-ylidene]-3-oxo-butyric acid methyl ester (12 mmol)
at RT. The resulting mixture was stirred at RT for 1 hour, refluxed for 2 h, let cool down and
stirred at RT for 16 h. The oily residue obtained after removing the volatiles *in vacuo* was
purified by MPLC (10 g SiO₂ cartridge, eluent 90 % iso-hexane – 10 % EtOAc) to give 0.38g
15 of 1-(5-Bromo-2-
hydroxy-benzyl)-5-methyl-1H-pyrazole-4-carboxylic acid methyl ester, **5** and 1-(5-Bromo-2-
hydroxy-benzyl)-3-methyl-1H-pyrazole-4-carboxylic acid methyl ester **6** as a mixture.

LC-MS: m/z 326 M + H⁺

STEP 2

1-[5-Bromo-2-(2-ethyl-butoxy)-benzyl]-5-methyl-1H-pyrazole-4-carboxylic acid methyl ester, 6.




5

The title compound was prepared following the method in Example 1, Step 3.

STEP 3

1-[5-Bromo-2-(2-ethyl-butoxy)-benzyl]-5-methyl-1H-pyrazole-4-carboxylic acid, 7.


10




The title compound was prepared following the method in Example 1, Step 4.

¹H-NMR (CDCl₃, 300 MHz) δ 8.02 (s, 1H, ArH), 7.37 (dd, 1H, ArH), 6.83 (d, 1H, ArH), 6.78 (d, 1H, ArH), 5.21 (s, 2H, ArCH₂), 3.90 (d, 2H, CH₂), 2.53 (s, 3H, CH₃), 1.71 (m, 1H, CH), 1.48 (m, 4H, CH₂), 0.96 (t, 6H, CH₃).

LC-MS: m/z 396 M + H⁺

EXAMPLE 3**1-(5-BROMO-2-HYDROXY-BENZYL)-3-METHYL-1H-PYRAZOLE-4-CARBOXYLIC ACID METHYL ESTER, 9.**

5


STEP 1**1-[5-Bromo-2-(2-ethyl-butoxy)-benzyl]-3-methyl-1H-pyrazole-4-carboxylic acid methyl ester, 8.**

10

The title compound was prepared using the mixture from Example 2, Step 1 following the method in Example 1, Step 3.

¹H-NMR (CDCl₃, 300 MHz) δ 7.94 (s, 1H, ArH), 7.35 (dd, 1H, ArH), 6.78 (d, 1H, ArH), 6.77 (s, 1H, ArH), 5.29 (s, 2H, ArCH₂), 3.90 (d, 2H, CH₂), 3.85 (s, 3H, CH₃), 2.51 (s, 3H, CH₃), 1.71 (m, 1H, CH), 1.49 (m, 4H, CH₂), 0.95 (t, 6H, CH₃).

LC-MS: m/z 410 M + H⁺.


STEP 2**1-(5-Bromo-2-hydroxy-benzyl)-3-methyl-1H-pyrazole-4-carboxylic acid methyl ester, 9.**


5 The title compound was prepared following the method in Example 1, Step 4.

¹H-NMR (CDCl₃, 300 MHz) δ 7.84 (s, 1H, ArH), 7.42 (dd, 1H, ArH), 7.25 (d, 1H, ArH), 6.80 (d, 1H, ArH), 5.22 (s, 2H, ArCH₂), 3.87 (d, 2H, CH₂), 2.50 (s, 3H, CH₃), 1.67 (m, 1H, CH), 1.44 (m, 4H, CH₂),
 10 0.92 (t, 6H, CH₃).
 LC-MS: m/z 396 M + H⁺.

EXAMPLE 4**1-[5-CHLORO-2-(2-ETHYL-BUTOXY)-BENZYL]-1H-PYRAZOLE-4-CARBOXYLIC ACID, 14.**

15



STEP 1**5-Chloro-2-(2-ethyl-butoxy)-benzaldehyde, 10.**


5 To a solution of 5-chloro-2-hydroxybenzaldehyde, 2.1g (13.4 mmol) DMF (50 mL) under N₂ atmosphere at RT was added 3-(chloromethyl)pentane (1.92g 15.6 mmol), K₂CO₃ (4.5g, 32.6 mmol) and tetrabutylammonium iodide (0.35g, 0.9 mmol). The resulting mixture was stirred at 120° C for 5 hours. The mixture was partitioned between water (80 ml) and EtOAc (80 ml). The organic layer was washed with water (80 ml) followed by brine (80 ml), dried over
 10 (Na₂SO₄), filtered and the volatiles were removed *in vacuo*. The crude product was purified on silica to yield to yield 2.83g of 5-Chloro-2-(2-ethyl-butoxy)-benzaldehyde, **10**.

1H-NMR, (CDCl₃, 300 MHz) δ 10.46 (s, 1H, ArCHO), 7.80 (d, 1H, ArH), 7.49 (dd, 1H, ArH), 6.97 (d, 1H, ArH), 3.99 (d, 2H, CH₂), 1.75 (m, 1H, CH), 1.52 (m, 4H, CH₂), 0.97 (t,
 15 6H, CH₃).

LC-MS: m/z 241 M + H⁺.

STEP 2**[5-Chloro-2-(2-ethyl-butoxy)-phenyl]-methanol, 11.**

20



A solution of 5-Chloro-2-(2-ethyl-butoxy)-benzaldehyde, **10**, (2.83g 11.8 mmol), MeOH (50 mL) was cooled to +5 °C under N₂ atmosphere and NaBH₄ (0.54g, 14.2 mmol) was added.

The mixture was allowed to warm to RT over 2 hours and the volatiles were removed *in vacuo*. The reaction mixture was partitioned between water and CH₂Cl₂. The organic layer was washed with sat. brine, dried (Na₂SO₄) and evaporated to dryness to give 2.61g of 5-chloro-2-(2-ethyl-butoxy)-phenyl]-methanol, **11** as a pale yellow oil.


5

¹H-NMR (CDCl₃, 300 MHz) δ 7.30 (d, 1H, ArH), 7.22 (dd, 1H, ArH), 6.82 (d, 1H, ArH), 4.68 (d, 2H, CH₂), 3.91 (d, 2H, CH₂), 2.22 (t, 1H, CH₂OH), 1.71 (m, 1H, CH), 1.50 (m, 4H, CH₂), 0.96 (t, 6H, CH₃).

10 LC-MS: m/z 243 M + H⁺.

STEP 3

Methanesulfonic acid 5-chloro-2-(2-ethyl-butoxy)-benzyl ester, **12**.




15 A solution of [5-Chloro-2-(2-ethyl-butoxy)-phenyl]-methanol, **11**, (0.3g g 1.24 mmol), diisopropyl-ethyl amine (0.24mL, 1.36 mmol) and methanesulfonic anhydride (0.24g 1.36 mmol) in CH₂Cl₂ (8 mL) was stirred under N₂ atmosphere at RT for 2 hours. The reaction mixture was partitioned between water and CH₂Cl₂. The organic layer was washed with sat. brine, dried (MgSO₄) and evaporated to dryness to give mesylate **12**, 0.39g.

20

¹H-NMR (CDCl₃, 300 MHz) δ 7.38 (d, 1H, ArH), 7.32 (dd, 1H, ArH), 6.86 (d, ArH), 5.26 (d, 2H, CH₂), 3.90 (d, 2H, CH₂), 3.01 (s, 3H, CH₃), 1.71 (m, 1H, CH), 1.50 (m, 4H, CH₂), 0.95 (t, 6H, CH₃).


25

STEP 4**1-[5-Chloro-2-(2-ethyl-butoxy)-benzyl]-1H-pyrazole-4-carboxylic acid ethyl ester, 13.**

- 5 To a solution of ethyl-4-pyrazole carboxylate, 0.094g (0.67 mmol) DMF (5 mL) under N₂ atmosphere at RT was added NaH (0.033g 0.81 mmol, 60% in mineral oils). The resulting mixture was stirred for 30 minutes. A solution of Methanesulfonic acid 5-chloro-2-(2-ethyl-butoxy)-benzyl ester, **12**, in DMF (2 mL) was the added and the mixture was stirred for 16 hours. The mixture was poured into water and the volatiles were removed *in vacuo*. The
- 10 crude product was purified on silica to yield to yield 0.1g of 1-[5-Chloro-2-(2-ethyl-butoxy)-benzyl]-1H-pyrazole-4-carboxylic acid ethyl ester, **13**.


¹H-NMR (CDCl₃, 300 MHz) δ 7.94 (s, 1H, ArH), 7.87 (s, 1H, ArH), 7.27 (dd, 1H, ArH), 7.08 (d, 1H, ArH), 6.84 (d, 1H, ArH), 5.29 (s, 2H, ArCH₂), 4.30 (q, 2H, CH₃CH₂), 3.88 (d, 2H, CH₂), 1.67 (m, 1H, CH), 1.47 (m, 4H, CH₂), 1.35 (t, 3H, CH₂CH₃), 0.93 (t, 6H, CH₃). LC-MS: m/z 365 M + H⁺.


15

STEP 5**1-[5-Chloro-2-(2-ethyl-butoxy)-benzyl]-1H-pyrazole-4-carboxylic acid, 14.**

5 The title compound was prepared following the method in Example 1, Step 4.

¹H-NMR (CDCl₃, 300 MHz) δ 8.00 (s, 1H, ArH), 7.93 (s, 1H, ArH), 7.29 (dd, 1H, ArH), 7.14 (d, 1H, ArH), 6.85 (d, 1H, ArH), 5.31 (d, 2H, ArCH₂), 3.88 (d, 2H, CH₂), 1.67 (m, 1H, CH), 1.43 (m, 4H, CH₂),
 10 1.35 (t, 3H, CH₂CH₃), 0.92 (t, 6H, CH₃).
 LC-MS: m/z 337 M + H⁺.

EXAMPLE 5**1-[5-CHLORO-2-(2-ETHYL-BUTOXY)-BENZYL]-3,5-DIMETHYL-1H-PYRAZOLE-4-CARBOXYLIC ACID, 16.**


STEP 1**1-[5-Chloro-2-(2-ethyl-butoxy)-benzyl]-3,5-dimethyl-1H-pyrazole-4-carboxylic acid ethyl ester, 15.**

5

The title compound was prepared following the method in Example 4, Step 4.

$^1\text{H-NMR}$ (CDCl_3 , 300 MHz) δ 7.18 (dd, 1H, ArH), 6.81 (d, 1H, ArH), 6.55 (d, 1H, ArH), 5.23 (d, 2H, ArCH₂), 4.14 (q, 2H, CH₃CH₂), 3.90 (d, 2H, CH₂), 2.47 (s, 3H, CH₃), 2.45 (s, 3H, CH₃), 1.71 (m, 1H, CH), 1.50 (m, 4H, CH₂), 1.38 (t, 3H, CH₂CH₃), 0.95 (t, 6H, CH₃).
LC-MS: m/z 393 M + H⁺.

15


STEP 2**1-[5-Chloro-2-(2-ethyl-butoxy)-benzyl]-3,5-dimethyl-1H-pyrazole-4-carboxylic acid, 16.**

The title compound was prepared following the method in Example 1, Step 4.

¹H-NMR (CDCl₃, 300 MHz) δ 7.20 (dd, 1H, ArH), 6.82 (d, 1H, ArH), 6.62 (d, 1H, ArH), 5.26 (s, 2H, ArCH₂), 3.91 (d, 2H, CH₂), 2.51 (s, 3H, CH₃), 2.50 (s, 3H, CH₃), 1.72 (m, 1H, CH), 1.50 (m, 4H, CH₂), 1.38 (t, 3H, CH₂CH₃), 0.96 (t, 6H, CH₃).
 LC-MS: m/z 365 M + H⁺.

EXAMPLE 6

10 **1-[5-CHLORO-2-(2-ETHYL-BUTOXY)-BENZYL]-3-PROPYL-1H-PYRAZOLE-4-CARBOXYLIC ACID, 18.**



STEP 1


15 **1-[5-Chloro-2-(2-ethyl-butoxy)-benzyl]-3-propyl-1H-pyrazole-4-carboxylic acid ethyl ester, 17.**

The title compound and its region-isomer (2:1 mixture) were prepared following the method in Example 4, Step 4. The mixture was in subsequent step.

20 LC-MS: m/z 407 M + H⁺.


STEP 2**1-[5-Chloro-2-(2-ethyl-butoxy)-benzyl]-3-propyl-1H-pyrazole-4-carboxylic acid, 18.**

5



The title compound was prepared following the method in Example 1, Step 4.


- 10 $^1\text{H-NMR}$ (CDCl_3 , 300 MHz) δ 8.02 (s, 1H, ArCOOH), 7.22 (dd, 1H, ArH), 7.06 (d, 1H, ArH), 6.83 (d, 1H, ArH), 6.71 (d, 1H, ArH), 5.32 (d, 2H, ArCH₂), 3.91 (d, 2H, CH₂), 2.93 (t, 2H, ArCH₂CH₂), 1.83 (m, 1H, CH), 1.56 (m, 2H, CH₂CH₂), 1.50 (m, 4H, CH₂), 0.96 (t, 6H, CH₃), 0.95 (t, 3H, CH₂CH₃).
- 15 LC-MS: m/z 379 M + H⁺.

EXAMPLE 7**1-[5-CHLORO-2-(2-ETHYL-BUTOXY)-BENZYL]-5-PROPYL-1H-PYRAZOLE-4-CARBOXYLIC ACID, 20.**

5

STEP 1**1-[5-Chloro-2-(2-ethyl-butoxy)-benzyl]-5-propyl-1H-pyrazole-4-carboxylic acid ethyl ester, 19.**

10



The title compound and its region-isomer (2:1 mixture) were prepared following the method in Example 4, Step 4. The mixture was used in subsequent step.

15

LC-MS: m/z 407 M + H⁺.

STEP 2**1-[5-Chloro-2-(2-ethyl-butoxy)-benzyl]-5-propyl-1H-pyrazole-4-carboxylic acid, 20**

The title compound was prepared following the method in Example 1, Step 4.

5


$^1\text{H-NMR}$ (CDCl_3 , 300 MHz) δ 7.83 (d, 1H, ArH), 7.27 (dd, 1H, ArH), 7.06 (d, 1H, ArH), 6.84 (d, 1H, ArH), 5.24 (s, 2H, ArCH₂), 3.88 (d, 2H, CH₂), 2.88 (t, 2H, ArCH₂CH₂), 1.74 (m, 2H, CH₂CH₂), 1.66 (m, 1H, CH), 1.43 (m, 4H, CH₂), 0.99 (t, 3H, CH₂CH₃), 0.91 (t, 6H, CH₃).

10


LC-MS: m/z 379 M + H⁺.

EXAMPLE 8**1-[2-(2-ETHYL-BUTOXY)-5-TRIFLUOROMETHYL-BENZYL]-5-METHYL-1H-PYRAZOLE-4-CARBOXYLIC ACID, 25**

15

**STEP 1****2-Bromomethyl-1-methoxy-4-trifluoromethyl-benzene, 21.**

20




To a solution of 2-methoxy-5-trifluoromethyl alcohol, 1g (4.85 mmol) DCM (20 mL) under N₂ atmosphere at RT was added PBr₃ (5.82 mL, 5.82 mmol, 1M in DCM). The resulting mixture was stirred for 16 hours. The reaction mixture was quenched with saturated NaHCO₃ and partitioned between aqueous phase and CH₂Cl₂. The organic layer was washed with sat.
 5 brine, dried (MgSO₄) and evaporated to dryness to give 1.1g of 2-bromomethyl-1-methoxy-4-trifluoromethyl-benzene, 21.

¹H-NMR (CDCl₃, 300 MHz) δ 7.61 (s, 1H, ArH), 7.58 (d, 1H, ArH), 6.97 (d, 1H, ArH), 4.56 (d, 2H, CH₂), 3.97 (d, 2H, CH₂).

10 LC-MS: m/z 270 M + H⁺.


STEP 2

1-(2-Methoxy-5-trifluoromethyl-benzyl)-5-methyl-1H-pyrazole-4-carboxylic acid ethyl ester, 22.



To a solution of ethyl-4-pyrazole carboxylate, 1.1g (4.09 mmol) in DMF (37 mL) under N₂ atmosphere at RT was added NaH (0.22g, 5.32 mmol, 60% in mineral oils). The resulting mixture was stirred for 30 minutes. A solution of 2-bromomethyl-1-methoxy-4-trifluoromethyl-benzene 21 in DMF (2 mL) (0.69g, 4.5 mmol) was then added and the
 20 mixture was stirred for 16 hours. The mixture was poured into water and the volatiles were removed *in vacuo*. The crude product was purified on silica to yield 1g of 1-[5-Chloro-2-(2-ethyl-butoxy)-benzyl]-1H-pyrazole-4-carboxylic acid ethyl ester, 22 as a 3:2 mixture with its regioisomer. The mixture was used in subsequent step.

25 LC-MS: m/z 343 M + H⁺.

STEP 3**1-(2-Hydroxy-5-trifluoromethyl-benzyl)-5-methyl-1H-pyrazole-4-carboxylic acid ethyl ester, 23.**

5

To a solution of 1-(2-Methoxy-5-trifluoromethyl-benzyl)-5-methyl-1H-pyrazole-4-carboxylic acid ethyl ester, 22, 0.2 g (0.60 mmol) in dry DCM (25 ml) under N₂ atm at 0° C, 4.4 ml of boron tribromide (1M in DCM) was added, The solution was allowed to warm to room temperature. The mixture was stirred for 24 hours, quenched with MeOH and refluxed for 3


10 hours. Cooled to room temperature, water was added, extracted with EtOAc and wash with brine. After drying over MgSO₄ solvents were removed in vacuo and the crude product was purified on silica to yield 0.18g of 1-(2-Chloro-5-hydroxy-benzyl)-1H-indazole-5-carboxylic acid methyl ester, 23 as a 3:2 mixture with its regio isomer. The mixture was used in subsequent step.

15

LC-MS: m/z 329 M + H⁺.

STEP 4

1-[2-(2-Ethyl-butoxy)-5-trifluoromethyl-benzyl]-5-methyl-1H-pyrazole-4-carboxylic acid, ethyl ester, 24



5


The title compound was prepared following the method in Example 1, Step 3, as a 3:2 mixture with its regioisomer. The mixture was used in subsequent step.

LC-MS: m/z 413 $M + H^+$.

10

STEP 5

1-[2-(2-Ethyl-butoxy)-5-trifluoromethyl-benzyl]-5-methyl-1H-pyrazole-4-carboxylic acid, 25.



15


The title compound was prepared following the method in Example 1, Step 4. The title isomer was separated from the mixture by RP-HPLC.

$^1\text{H-NMR}$ (CDCl_3 , 300 MHz) δ 8.01 (s, 1H, ArH), 7.54 (m, 1H, ArH), 7.00 (m, 1H, ArH), 6.98 (m, 1H, ArH), 5.34 (s, 2H, ArCH₂), 3.98 (d, 2H, CH₂), 2.54 (s, 3H, CH₃), 1.74 (m, 1H, CH), 1.49 (m, 4H, CH₂), 0.96 (t, 6H, CH₃).

LC-MS: m/z 385 M + H⁺

EXAMPLE 9


1-[2-(2-ETHYL-BUTOXY)-5-TRIFLUOROMETHYL-BENZYL]-3-METHYL-1H-PYRAZOLE-4-CARBOXYLIC ACID, 26.




The title compound was prepared from the product of Example 8 step 4 following the method in Example 1, Step 4. The title isomer was separated from the mixture by RP-HPLC.

$^1\text{H-NMR}$ (CDCl_3 , 300 MHz) δ 7.84 (s, 1H, ArH), 7.60 (m, 1H, ArH), 7.41 (m, 1H, ArH), 6.99 (d, 1H, ArH), 5.28 (s, 2H, ArCH₂), 3.95 (d, 2H, CH₂), 2.47 (s, 3H, CH₃), 1.69 (m, 1H, CH), 1.45 (m, 4H, CH₂), 0.92 (t, 6H, CH₃).

LC-MS: m/z 385 M + H⁺

EXAMPLE 10**1-[5-CHLORO-2-(2-ETHYL-BUTOXY)-BENZYL]-5-METHYL-1H-PYRAZOLE-4-CARBOXYLIC ACID, 28.**

5

STEP 1**1-[5-Chloro-2-(2-ethyl-butoxy)-benzyl]-5-methyl-1H-pyrazole-4-carboxylic acid ethyl ester, 27.**

The title compound was prepared following the method in Example 4, Step 4.

10 $^1\text{H-NMR}$ (CDCl_3 , 300 MHz) δ 8.01 (s, 1H, ArH), 7.20 (dd, 1H, ArH), 6.82 (d, 1H, ArH), 6.61 (d, 1H, ArH), 5.29 (s, 2H, ArCH₂), 4.32 (q, 2H, CH₃CH₂), 3.90 (d, 2H, CH₂), 2.50 (s, 3H, CH₃), 1.71 (m, 1H,


CH), 1.49 (m, 4H, CH_2), 1.38 (t, 2H, CH_3CH_2), 0.96 (t, 6H, CH_3).

LC-MS: m/z 379 M + H⁺

5

STEP 2

1-[5-Chloro-2-(2-ethyl-butoxy)-benzyl]-5-methyl-1H-pyrazole-4-carboxylic acid, 28.




The title compound was prepared following the method in Example 1, Step 4.

¹H-NMR (CDCl₃, 300 MHz) δ 8.03 (s, 1H, ArH), 7.23 (dd, 1H, ArH), 6.83 (d, 1H, ArH), 6.69 (d, 1H, ArH), 5.31 (s, 2H, ArCH₂), 3.92 (d, 2H, CH₂), 2.53 (s, 3H, CH₃), 1.72 (m, 1H, CH), 1.49 (m, 4H, CH₂), 0.96 (t, 6H, CH₃).

LC-MS: m/z 351 M + H⁺

15

EXAMPLE 11**1-(5-CHLORO-2-ISOBUTOXY-BENZYL)-5-METHYL-1H-PYRAZOLE-4-CARBOXYLIC ACID, 29.**

5


The title compound was prepared following the methods described for Example 8 and using the appropriate starting materials and reagents

$^1\text{H-NMR}$ (CDCl_3 , 300 MHz) δ 8.05 (s, 1H, ArH), 7.20 (dd, 1H, ArH), 6.80 (d, 1H, ArH), 6.70 (d, 1H, ArH), 5.31 (s, 2H, ArCH₂), 3.78 (d, 2H, CH₂), 2.55 (s, 3H, CH₃), 2.15 (m, 1H, CH), 1.03 (d, 6H, CH₃).
LC-MS: m/z 323 M + H⁺

10

EXAMPLE 12**1-(5-CHLORO-2-CYCLOPENTYLMETHOXY-BENZYL)-5-METHYL-1H-PYRAZOLE-4-CARBOXYLIC ACID, 30**

15



The title compound was prepared following the methods described for Example 8 and using the appropriate starting materials and reagents


¹H-NMR (DMSO, 300 MHz) δ 7.55 (s, 1H, ArH), 7.33 (dd, 1H, ArH), 7.05 (d, 1H, ArH), 6.80 (m, 1H, ArH), 5.25 (s, 2H, ArCH₂), 3.90 (d, 2H, CH₂), 2.55 (s, 3H, CH₃), 2.27 (m, 1H, CH), 1.75 (m, 2H, CH₂-CH₂), 1.6 (m, 4H, -CH₂-CH₂-), 1.30 (m, 2H, -CH₂-CH₂-).

LC-MS: m/z 349 M + H⁺

10

EXAMPLE 13

1-(5-BROMO-2-ISOBUTOXY-BENZYL)-5-METHYL-1H-PYRAZOLE-4-CARBOXYLIC ACID, 31.




15 The title compound was prepared following the methods described for Example 8 and using the appropriate starting materials and reagents.

¹H-NMR (CDCl₃, 300 MHz) δ 8.03 (s, 1H, ArH), 7.35 (dd, 1H, ArH), 6.87 (s, 1H, ArH), 6.75 (d, 1H, ArH), 5.31 (s, 2H, ArCH₂), 3.75 (d, 2H, CH₂), 2.55 (s, 3H, CH₃), 2.15 (m, 1H, CH), 1.03 (d, 6H, CH₃).

20

LC-MS: m/z 369 M + H⁺

25


EXAMPLE 14**1-[5-BROMO-2-(2,2-DIMETHYL-PROPOXY)-BENZYL]-5-METHYL-1H-PYRAZOLE-4-CARBOXYLIC ACID, 32**

5

The title compound was prepared following the methods described for Example 8 and using the appropriate starting materials and reagents.

$^1\text{H-NMR}$ (CDCl_3 , 300 MHz) δ 8.05 (s, 1H, ArH), 7.35 (dd, 1H, ArH), 6.80 (s, 1H, ArH), 6.75 (d, 1H, ArH), 5.40 (s, 2H, ArCH₂), 3.65 (s, 2H, CH₂), 2.52 (s, 3H, CH₃), 1.05 (s, 9H, CH₃).

LC-MS: m/z 383 $\text{M} + \text{H}^+$

EXAMPLE 15**1-[2-(2-ETHYL-BUTOXY)-5-TRIFLUOROMETHOXY-BENZYL]-5-METHYL-1H-PYRAZOLE-4-CARBOXYLIC ACID, 33**


The title compound was prepared following the methods described for Example 8 and using the appropriate starting materials and reagents.

$^1\text{H-NMR}$ (CDCl_3 , 300 MHz) δ 8.05 (s, 1H, ArH), 7.15 (dd, 1H, ArH), 6.90 (d, 1H, ArH), 6.60 (d, 1H, ArH), 5.32 (s, 2H, ArCH₂), 3.95 (d, 2H, CH₂), 2.55 (s, 3H, CH₃), 1.75 (m, 1H, CH), 1.52 (q, 4H, CH₂), 1.00 (t, 6H, CH₃).

LC-MS: m/z 401 $\text{M} + \text{H}^+$


EXAMPLE 16

5-AMINO-1-[5-BROMO-2-(2-ETHYL-BUTOXY)-BENZYL]-1H-PYRAZOLE-4-CARBOXYLIC ACID, 36



STEP 1

5-Amino-1-(5-bromo-2-hydroxy-benzyl)-1H-pyrazole-4-carboxylic acid, 34.



A suspension of N'-(5-bromo-2-hydroxy-benzyl)-hydrazinecarboxylic acid tert-butyl ester **1** (1g, 3.1 mmol) in a mixture of CH_2Cl_2 (8 mL) and TFA (8 mL) was stirred at RT for 2 hours.

The volatiles were removed *in vacuo*. The residue was dissolved in abs. EtOH (15 mL) and ethyl-2-cyano-3-ethoxyacrylate (0.55 g, 3.3 mmol) was added at RT. The resulting mixture was refluxed for 6 h, let cool down and stirred at RT for 16 h.


- 5 The white solid residue obtained was suspended with EtOAc (10ml) volatiles were removed *in vacuo*. The remaining oily residue was triturated with ether, collected and washed once with ether to give 0.3g of the title compound as a white solid.

¹H-NMR(DMSO-D₆, 300 MHz) δ 10.17 (s, 1H, ArOH), 7.53 (s, 1H, ArH), 7.27 (dd, 1H, ArH), 6.80 (d, 1H, ArH), 6.71 (d, 1H, ArH), 6.33 (s, 2H, ArNH₂), 5.05 (s, 2H, ArCH₂), 4.17 (q, 2H, -CH₂CH₃), 1.25 (t, 3H, -CH₂CH₃).

LC-MS: m/z 340,342 M + H⁺

STEP 2


- 15 **5-amino-1-[5-bromo-2-(2-ethyl-butoxy)-benzyl]-1h-pyrazole-4-carboxylic acid ethyl ester, 35**



The title compound was prepared following the method in Example 1, Step 3.

20 ¹H-NMR(CDCl₃, 300 MHz) δ 7.67 (s, 1H, ArH), 7.39 (dd, 1H, ArH), 7.26 (d, 1H, ArH), 6.82 (d, 1H, ArH), 5.23 (s, 2H, ArNH₂), 5.10 (s, 2H, ArCH₂), 4.28 (q, 2H, -CH₂CH₃), 3.95 (dd, 2H, CH₂), 1.73 (m, 1H, CH), 1.51 (m, 4H, CH₂), 1.35 (t, 3H, -CH₂CH₃), 0.97 (t, 6H, CH₃).

25 LC-MS: m/z 424,426 M + H⁺

STEP 3**5-amino-1-[5-bromo-2-(2-ethyl-butoxy)-benzyl]-1h-pyrazole-4-carboxylic acid, 36**

The title compound was prepared following the method in Example 1, Step 4

5

¹H-NMR(CDCl₃, 300 MHz) δ 7.72 (s, 1H, ArH), 7.40 (dd, 1H, ArH), 7.32 (d, 1H, ArH), 6.83 (d, 1H, ArH), 5.32 (s, 2H, ArNH₂), 5.11 (s, 2H, ArCH₂), 3.95 (dd, 2H, CH₂), 1.74 (m, 1H, CH), 1.52 (m, 4H, CH₂), 1.35 (t, 3H, -CH₂CH₃), 0.97 (t, 6H, CH₃).

LC-MS: m/z 396,398 M + H⁺

10

The above compounds were tested for PG antagonist activity as follows using human recombinant prostanoid receptor (DP₁, EP₁₋₄, FP, IP and TP) stable cell lines:

15

In order to measure the response of G_s and G_i coupled prostanoid receptors as a Ca²⁺ signal, chimeric G protein cDNAs were used. Stable cell lines over-expressing human prostanoid DP₁, EP₁₋₄, FP, IP, and TP receptors were established as follows:

20

Briefly, human prostanoid DP₁, EP₂, and EP₄ receptor cDNAs were co-transfected with chimeric G_{qs} cDNA containing a haemagglutinin (HA) epitope; human prostanoid EP₃ receptors were co-transfected with chimeric G_{qi}-HA; human EP₁, FP, IP, and TP receptor cDNAs were expressed with no exogenous G-proteins. G_{qs} and G_{qi} chimeric cDNAs (Molecular Devices, Sunnyvale, CA, U.S.A.), as well as cDNAs of prostanoid receptors, were cloned into a pCEP4 vector with a hygromycin B selection marker. Transfection into HEK-293 EBNA (Epstein-Barr virus nuclear antigen) cells was achieved by the FuGENE^{*} 6 transfection Reagent (Roche Applied Science, Indianapolis, IN, USA). Stable transfectants were selected according to hygromycin resistance. Because G_{qs} and G_{qi} contained an HA

25

Trademark*

epitope, G-protein expression was detected by Western blotting analysis using anti-mouse HA monoclonal antibody and horseradish peroxidase (HRP)-conjugated secondary antibody, while functional expression of prostanoid receptors was detected by FLIPR screening (Matias *et al.*, 2004). These stable cell lines were validated using previously published antagonists at 10 μ M against serial dilutions of standard agonists by FLIPR functional assays for Ca²⁺ Signaling (as described below).

Ca²⁺ signaling studies were performed using a FLIPR TETRA system (Molecular Devices, Sunnyvale, CA, USA) in the 384-format. This is a high-throughput instrument for cell-based assays to monitor Ca²⁺ signaling associated with GPCRs and ion channels. Cells were seeded at a density of 5 x 10⁴ cells/well in BioCoat poly-D-lysine coated, black wall, clear bottom 384-well plates (BD Biosciences, Franklin lakes, NJ, USA) and allowed to attach overnight in an incubator at 37°C. The cells were then washed twice with HBSS-HEPES buffer (Hanks' balanced salt solution without bicarbonate and phenol red, 20mM HEPES, pH 7.4) using an ELx405 Select CW Microplate Washer (BioTek, Winooski, VT, USA). After 60 min of dye-loading in the dark using the Ca²⁺-sensitive dye Fluo-4AM (Invitrogen, Carlsbad, CA, USA), at a final concentration of 2 x 10⁻⁶M, the plates were washed 4 times with HBSS-HEPES buffer to remove excess dye and leaving 50 μ l of buffer in each well. The plates were then placed in the FLIPR TETRA instrument and allowed to equilibrate at 37°C. AGN-211377 was added in a 25 μ l volume to each well to give final concentrations of 0.1 μ M, 0.3 μ M, 1 μ M, 3 μ M, 10 μ M, and 30 μ M; or 0.067 μ M, 0.1 μ M, 0.2 μ M, 0.3 μ M, 0.67 μ M, and 1 μ M for cells over-expressing TP receptors. After 4.5 minutes, a 7-point serial dilution of the standard agonist for the corresponding receptor, in a 25 μ l volume was injected at the final concentrations from 10⁻¹¹M to 10⁻⁵M in 10-fold serial dilution increments for cells expressing human recombinant DP₁, EP₁, EP₂, EP₃, EP₄, FP, and IP receptors. The dose range for the standard agonist for human recombinant TP receptors was from 10⁻¹²M to 10⁻⁶M. HBSS-HEPES buffer was used as the negative control for the standard agonists. Cells were excited with LED (light emitting diode) excitation at 470-495nm and emission was measured through an emission filter at 515-575nm. Assay plates were read for 3.5 minutes using the FLIPR^{TETRA}. The peak increase in fluorescence intensity was recorded for each well. On each plate, negative controls, dose response of positive controls, and co-treatments of antagonist-agonist for each dose were in triplicates. Standard agonists were as follows: DP =BW 245C, EP₁-EP₄=PGE₂, FP =17-phenyl-PGF_{2 α} , IP =Cicaprost, and TP =U-46619. The peak

fluorescence change in each well containing drug was expressed relative to vehicle controls with the standard agonist at 10^{-6} M (the positive control). To obtain concentration-response curves, compounds were tested in triplicate in each plate over the desired concentration range.

5

Ca²⁺ Signal Studies on Human Recombinant Prostanoid Receptor DP₂

FLIPR functional assays were conducted at Millipore to monitor the activity anti-asthmatic against human DP₂ receptors stably expressed in the Chem-5 proprietary host cell line generated by Millipore. Prior to standard agonist addition, the compounds were spotted at 10 μ M along with vehicle control (1% Ethanol in HBSS-HEPES buffer) across the assay wells. The assay plate was incubated at room temperature for 10 minutes in the dark. Then an 8-point serial dilution dose response from 10^{-12} M to 10^{-5} M of the standard agonist PGD₂ was performed. Assay plates were read for 90 seconds using the FLIPR^{TETRA}. The fluorescence measurements were collected to calculate IC₅₀ values. The assays were done at least 3 times to give n=3.

15

Data Processing

All plates were subjected to appropriate baseline corrections. Maximum fluorescence values were exported. The raw data of n=1 was first processed by Activity Base using nonlinear regression curve fit to calculate the percentage activity of each data point relative to the positive control ($=10^{-6}$ M of the standard agonist). Then n=3 of this data were exported to GraphPad Prism 4 to calculate the average EC₅₀ of the standard agonist, and the IC₅₀ (the concentration of the antagonist required to inhibit half the standard agonist activity) were calculated using nonlinear regression curve fit, with constraints of bottom constant equal to 0 and top constant equal to 100. Calculation of Kb = [Antagonist Concentration]/ (IC₅₀/EC₅₀-1). When no antagonism was detected or when Kb $\geq 10,000$ nM, the antagonist is defined as not active (NA).

20

25

30

The results of the above testing are reported in TABLE 1, below.

TABLE 1

Example	FP	DP	EP1	EP2	EP3	EP4	IP	TP
1	2700	400	170	NA	NA	100	4800	3
2	80	600	33	NA	6100	380	2400	12
3	400	1100	30	NA	NA	1300	1400	30
4	2000	1400	140	NA	NA	4800	3100	100
5	700	350	20	NA	NA	860	600	18
6	NA	5600	1500	8600	NA	4900	NA	500
7	NA	NA	640	NA	NA	3300	1800	150
8	200	1400	40	NA	NA	1600	NA	45
9	7200	3900	440	NA	NA	NA	NA	440
10	190	940	50	NA	3900	500	1300	6
11	500	4550	30	NA	NA	3300	8300	80
12	110	2500	30	NA	NA	600	2650	40
13	70	3500	30	NA	NA	2100	7700	20
14	90	3400	30	NA	NA	1300	NA	20
15	140	780	45	NA	NA	1500	10000	8
16	200	1600	60	NA	NA	300	5100	50

5

As shown in TABLE 1, the preferred compounds of this invention are pan antagonists having activity at the FP, DP, EP₁, EP₄ and TP receptors, but are inactive at the IP, EP₂ and EP₃ receptors. Thus, these compounds have a biological selectivity profile making them useful in treating diseases and conditions which are mediated by the EP₂ and/or EP₃ receptors, without the side effects mediated by the FP, DP, EP₁, EP₄ and TP receptors.

10

The 4-carboxylic pyrazoles included in the present invention, were compared to 3-carboxylic acids see TABLE 2, below.

15

TABLE 2

Example	FP	DP	EP1	EP2	EP3	EP4	IP	TP
17	300	2300	20	NA	NA	NA	NA	30
18	1100	500	60	NA	NA	5000	NA	<1
19	400	2400	20	NA	NA	NA	NA	7
20	230	85	<1	NA	NA	4200	NA	<1
21	70	1300	10	NA	9100	NA	NA	1

As shown in TABLE 2, the 3-carboxylic acid compounds are active at FP, EP1 and TP
 5 receptors but do not have significant activity at the EP4 receptor, In contrast the 4-carboxylic
 acids of the present invention are active at the FP, EP1, TP and EP4 receptors.

As a result, the 4-carboxylic acid compounds will exhibit more pronounced therapeutic
 benefit through blockade of the EP4 receptor whilst allowing EP2, EP3 and IP these receptors
 10 to maintain their inherent anti-inflammatory and anti-proliferative functions in response to
 endogenously present prostanoids.

Thus, the compounds of this invention compound may be administered to treat DP1, FP, EP1,
 TP and/or EP4 receptor mediated diseases or conditions.

For example, said condition or disease may be related to inflammation, or said DP1 , FP,
 EP1, TP and/or EP4 receptor mediated condition or disease may be selected from the group
 consisting of allergic conditions, asthma, allergic asthma, allergic rhinitis, uveitis and related
 disorders , atherosclerosis, blood coagulation disorders, bone disorders, cancer, cellular
 neoplastic transformations, chronic obstructive pulmonary diseases and other forms of lung
 20 inflammation, congestive heart failure, diabetic retinopathy, diseases or conditions requiring
 a treatment of anti-coagulation, diseases requiring control of bone formation and resorption,
 fertility disorders, , gangrene, glaucoma, hyperpyrexia, immune and autoimmune diseases,
 inflammatory conditions, metastatic tumor growth, migraine, mucus secretion disorders, nasal
 congestion, nasal inflammation, occlusive vascular diseases, ocular hypertension, ocular
 25 hypotension, osteoporosis, rheumatoid arthritis , pain, perennial rhinitis, pulmonary
 congestion, pulmonary hypotension, Raynaud's disease, rejection in organ transplant and by-

pass surgery, respiratory conditions, hirsutism , rhinorrhea, shock, sleep disorders, and sleep-wake cycle disorders.

Said compound may be administered as a surgical adjunct in ophthalmology for cataract
5 removal and artificial lens insertion , ocular implant procedures, photorefractive radial keratotomy and other ophthalmological laser procedures or as a surgical adjunct in a procedure involving skin incisions, relief of pain and inflammation and scar formation/keloids post-surgery, for treating sports injuries and general aches and pains in muscles and joints.

10 Preferably, said DP₁, FP, EP₁, TP , and/or EP₄ receptor mediated condition or disease is an EP₁ and/or EP₄ receptor mediated condition or disease.

Preferably, said DP₁, FP, EP₁ , TP and/or EP₄ receptor mediated condition or disease is an
allergic condition, e.g. an dermatological allergy, or an ocular allergy, or a respiratory
15 allergy, e.g. nasal congestion, rhinitis, and asthma.

Said condition or disease may be related to pain.

Said condition or disease may be selected from the group consisting of arthritis, migraine,
20 and headache.

Said condition or disease may be associated with the gastrointestinal tract, wherein said
condition or disease may be peptic ulcer, heartburn, reflux esophagitis, erosive esophagitis,
non-ulcer dyspepsia, infection by *Helicobacter pylori*, alrnyitis, and irritable bowel syndrome.
25

Said condition or disease may be selected from the group consisting of hyperalgesia and
allodynia, or said condition or disease may be related to mucus secretion, wherein said mucus
secretion is gastrointestinal, or occurs in the nose, sinuses, throat, or lungs.

30 Said condition or disease is related to abdominal cramping, e.g. said condition or disease may be irritable bowel syndrome.

Said condition or disease may be a bleeding disorder, or a sleep disorder, or mastocytosis.

Said condition or disease may be associated with elevated body temperature, or ocular hypertension and glaucoma, or ocular hypotension.

- 5 Said condition may relate to surgical procedures to treat pain, inflammation and other unwanted sequelae wherein said surgical procedure includes incision, laser surgery or implantation.

The present invention also relates to a method of treating inflammation resulting from inflammatory diseases characterized by monocytic infiltration caused by the secretion of
10 cytokines and/or chemokines by administration, to a patient in need of said treatment, of a pharmaceutical composition comprising a compound of the present invention.

The current finding that the compounds of this invention are effective in attenuating the production of TNF family cytokines (TNF α), and the classical interleukin-1 (IL-1) family
15 cytokines is especially important. These cytokines exert a broad spectrum of biological and pathological effects. They play key roles in inflammation and RA pathogenesis by stimulating the release of multiple proinflammatory cytokines, including themselves, through the NF κ B signaling pathway. Although alleviating the symptoms of RA in 50-65% of patients, a TNF α antibody is very expensive to use compared to chemically synthesized small
20 molecules, inconvenient to administer usually requiring injections, and has been linked to tuberculosis, lymphoma, and other adverse effects. Unlike a TNF α antibody that totally eliminates all circulating TNF α in the system; the compounds of this invention only attenuate the production of TNF α by inhibiting proinflammatory PG receptors. Therefore the adverse effects associated with a TNF α antibody in elevating infectious and cancerous tendency is
25 less likely.

Proinflammatory elements TNF, RANTES, and MCP-1 are involved in the cascade of events in the early and late stages of atherosclerosis. Plasma MCP-1 levels have been linked to cardiovascular disease risk factors in clinical studies. Platelet activation leads to the release
30 of MIP-1 α , RANTES, and IL-8, which attract leukocytes and further activate other platelets. These evidences provide a direct linkage between homeostasis, infection, and inflammation and the development of atherosclerosis. The compounds of this invention are able to target multiple biomarkers of inflammation, thrombosis, and atherothrombosis simultaneously,

which may confer pharmaceutical potential on the compounds of this invention in treating atherosclerosis and atherothrombosis. As a result, the compounds of this invention are unlikely to be associated with cardiovascular liability as in the case of the COXIBs, conversely it may even have a beneficial effect on cardiovascular function.

5

In summary, because of their ability to suppress the synthesis of some key proinflammatory cytokines/chemokines IL-8, MCP-1, MDC, RANTES, and TNF α , the compounds of the present invention are not only at least as effective as COXIBs and NSAIDs in RA treatment, but also are a safer therapy in RA treatment. They are also a potential therapy for cardiovascular diseases.

10

The compounds of this invention treat or prevent inflammation at least in part by the decreasing the amount of the secretion of certain cytokines and/ or chemokines that result from the exposure of the patient to a stimulant.

15

In particular, the secretion of VEGF, MIP-1 β , IL-8, , MCP-1, MDC, and RANTES is reduced in those instances where said secretions are triggered by lipopolysaccharides (LPS) and or TNF α .

20

Interleukin-8 (IL-8): functions as a potent chemo attractants and activator of neutrophils, IL-8 is produced in response to stimulation with either IL-1 or TNF α . IL-8 not only accounts for a significant proportion of the chemotactic activity for neutrophils in rheumatoid arthritis (RA) synovial fluids, but also is a potent angiogenic factor in the RA synovium.

25

Monocyte chemo attractant protein-1 (MCP-1, or CCL-2): is not only believed to play a role in inflammatory diseases characterized by monocytic infiltration, such as RA rheumatoid arthritis, psoriasis, and atherosclerosis, but is also implicated in other diseases, such as atopic dermatitis, renal disease, pleurisy, allergy and asthma, colitis, endometriosis, polymyositis and dermatomyositis, uveitis, restenosis, brain inflammation and obesity. MCP-1 also

30

controls leukocyte trafficking in vascular cells involved in diabetes and diabetes-induced atherosclerosis. MCP-1 antibodies are potential therapeutic agents for treating MCP-1/CCR2-mediated multiple inflammatory diseases.

Tumor necrosis factor α (TNF α): mainly secreted by macrophages and recognized for its importance in activating the cytokine cascade. TNF α stimulates the production of proinflammatory cytokines/chemokines, collagenases, metalloproteinases, and other inflammatory mediators; activates endothelial cells and neutrophils; promotes T- and B-cell growth, as well as stimulating bone resorption. The TNF α antibody infliximab not only decreases the production of local and systemic proinflammatory cytokines/chemokines, but also reduces serum MMP-3 production, nitric oxide synthase activity, VEGF release, and angiogenesis in inflamed joints.

Macrophage-derived chemokine (MDC) induces chemotaxis for monocyte-derived dendritic cells, activated T cells and natural killer (NK) cells (Ho *et al.*, 2003). Highly expressed by the three major cell types involved in allergic inflammation: eosinophils, basophils, and Th2 lymphocytes (Garcia *et al.*, 2005), as well as highly expressed in atopic dermatitis (Pivarcsi *et al.*, 2005), MDC plays a role in inflammatory diseases such as allergic asthma and atopic dermatitis (Ho *et al.*, 2003). Significantly enhanced in keratinocytes of patients with atopic dermatitis, MDC could be a candidate therapeutic target for inflammatory skin disease such as atopic dermatitis (Qi *et al.*, 2009). MDC is also implicated in disease activity of RA. After combination treatment with the disease-modifying anti-rheumatic drugs leflunomide and methotrexate in RA patients, plasma MCP-1 and MDC concentrations were significantly lower, and so was the recruitment of inflammatory cells into the sites of inflammation (Ho *et al.*, 2003). Moreover, MDC also amplify platelet activation and has been associated with the pathogenesis of atherosclerotic disease including thrombosis (Gleissner *et al.*, 2008).

Regulated on Activation, Normal T Cell Expressed and Secreted (RANTES) is a chemo attractant for blood monocytes, memory T-helper cells and eosinophils, and plays an active role in recruiting leukocytes into inflammatory sites. It also stimulates the release of histamine from basophils, activates eosinophils and causes hypodense eosinophils, which is associated with diseases such as asthma and allergic rhinitis. RANTES receptor CCR5 is also expressed on cells involved in atherosclerosis (e.g. monocytes/macrophages, T lymphocytes, or Th1-type cells), and is specialized in mediating RANTES-triggered atherosclerotic plaque formation (Zernecke *et al.*, 2008). Like MCP-1, stimulation with RANTES enhances production of IL-6 and IL-8 in RA fibroblast-like synovial cells; elevated MMP-3 production by chondrocytes, and inhibited proteoglycan synthesis and enhanced

proteoglycan release from the chondrocytes (Iwamoto *et al.*, 2008). Both MCP-1 and RANTES were found to play an important role in allergic lung inflammation, lung leukocyte infiltration, bronchial hyper-responsiveness, and the recruitment of eosinophils in the pathogenesis of asthma (Conti *et al.*, 2001). Similar to MCP-1, RANTES also enhances the inflammatory response within the nervous system, which plays an apparent role in the pathogenesis of multiple sclerosis (Conti *et al.*, 2001). Inhibitors for RANTES may provide clinical benefits in treating inflammation, CNS disorders, parasitic disease, cancer, autoimmune and heart diseases (Castellani *et al.*, 2007).

While the use of the compounds of this invention are shown to decrease the secretion of the above cytokines in Figures 2 through 9, it is believed that the compounds of this invention are effective to decrease the secretion of ENA-7, PAI-1, CD-10, G-CSF, GM-CSF, IL-1 α and IL-18, as well.

The compounds of this invention may be also tested for efficacy in treating uveitis as described below.

Arachidonate Induced Uveitis

The rational for this protocol is to use arachidonate to directly produce ocular anterior segment uveitis, as opposed to using lipopolysaccharide (LPS) to indirectly release arachidonic acid.

Induction of uveitis:

Conscious male or female Dutch-belted pigmented rabbits weighing 2.5 – 3 kg were used for all in vivo slit lamp studies. Four animals were employed per test group. The right eye of each animal receiving 35 μ l of topically administered test and the contralateral left eye of each animal receiving 35 μ l of topically administered vehicle (t = 0 minutes), followed 30 minutes later by treatment with 35 μ l of 0.5% sodium arachidonate onto the surface of both eyes (t = 30 minutes). Both eyes were examined by slit lamp 60 minutes following sodium arachdionate challenge (t = 90 minutes) at 16x magnification under both white light and blue light illumination at an approximate angle of 45° through 1 mm and 5 mm slit widths.

Measurement of anterior chamber leukocyte infiltration:

Anterior chamber leukocyte infiltration was measured using a numerical scoring system to estimate cell number per field defined by a 5 mm slit width: 0 = no cells per field (no response);

5

1 = 1 – 10 cells per field (mild); 2 = 11 – 20 cells per field (moderate); 3 = 26 – 50 cells per field (severe); 4 = >50 cells per field (florid). Results are reported as the mean score value $\pm$ S.E.M.


10 The compounds of this invention were tested according to the method described in “Characterization of Receptor Subtypes Involved in Prostanoid-Induced Conjunctival Pruritis and Their Role in Mediating Conjunctival Itching”, Vol. 279, No.1,(JPET)279, 137-142’ 1996 for their efficacy in alleviating itch. The results are reported in Figures 10 and 11. The results in both experiments showed a significantly lower number of itch-scratch episodes
15 with the use of the compounds of Figures 3 and 3(a) thereby indicating that the compounds of this invention are useful in treating allergic conjunctivitis..

The compounds of Figures 3 and 3(a) were tested for mutagenicity by means of the Ames Test using Strains TA 98 and TA 100. The results were negative for both compounds.

20

Finally, said condition that may be treated with the compounds of this invention may be related to pain and inflammation and post-surgical scar and keloid formation.

In view of the various diseases and conditions that may be treated with the compositions of
25 this invention there is provided a pharmaceutical product comprising a compound having the following formula:



Wherein X is O, NR₇ or (CH₂)_n, wherein n is 0 or an integer of 1 or 2;

Y is (CH₂)_m, wherein m is 0 or an integer of from 1 to 3;

- 5 Z is selected from the group consisting of O, S, SO, SO₂ and (CH₂)_p, wherein p is 0 or an integer of from 1 to 3;

W is hydrocarbyl or substituted hydrocarbyl;

- 10 R₁ is selected from the group consisting of OR₇, N(R₇)₂, and N(R₇)SO₂R₇;

R₂ is selected from the group consisting of H, hydroxy, alkyl, aryl, alkoxy, aryloxy, halogen, nitro, amino, cyano and hydroxy, halogen, nitro, amino and cyano-substituted alkyl, aryl, alkoxy or aryloxy;

15

R₄ is selected from the group consisting of H, NH₂, alkyl, nitrogen-substituted alkyl and halogen-substituted alkyl;

- 20 R₅ is selected from the group consisting of H, hydroxy, alkyl, aryl, alkoxy, aryloxy, halogen, nitro, amino, cyano and hydroxy, halogen, nitro, amino and cyano-substituted alkyl, aryl, alkoxy or aryloxy;

- 25 R₆ is selected from the group consisting of H, hydroxy, alkyl, aryl, alkoxy, aryloxy, halogen, nitro, amino, cyano and hydroxy, halogen, nitro, amino and cyano-substituted alkyl, aryl, alkoxy or aryloxy; and,

- 30 R₇ is selected from the group consisting of H, hydrocarbyl and substituted hydrocarbyl, e.g. carbocyclic aryl and alkyl or a pharmaceutically acceptable salt or a prodrug thereof, wherein said product is packaged and labeled for the treatment or prevention of a disease or condition selected from the group consisting of uveitis, allergic conditions, asthma, allergic asthma, allergic rhinitis, atherosclerosis, blood coagulation disorders, bone disorders, cancer, cellular neoplastic transformations, chronic obstructive pulmonary diseases and other forms of lung inflammation, congestive heart failure, diabetic retinopathy, diseases or conditions requiring

a treatment of anti-coagulation, diseases requiring control of bone formation and resorption, fertility disorders, hyperpyrexia, gangrene, glaucoma, hypothermia, immune and autoimmune diseases, inflammatory conditions, metastatic tumor growth, migraine, mucus secretion disorders, nasal congestion, nasal inflammation, occlusive vascular diseases, ocular hypertension, ocular hypotension, osteoporosis, pain, perennial rhinitis, pulmonary congestion, pulmonary hypotension, Raynaud's disease, rejection in organ transplant and bypass surgery, respiratory conditions, rheumatoid arthritis, rhinorrhea, shock, sleep disorders, sleep-wake cycle disorders, sports injuries, muscle aches and pains, and surgical adjunct for minimizing pain, inflammation and scar/keloid formation.

10

Those skilled in the art will readily understand that for administration the compounds disclosed herein can be admixed with pharmaceutically acceptable excipients which, per se, are well known in the art. Specifically, a drug to be administered systemically, it may be formulated as a powder, pill, tablet or the like, or as a solution, emulsion, suspension, aerosol, syrup or elixir suitable for oral or parenteral administration or inhalation.

15

For solid dosage forms, non-toxic solid carriers include, but are not limited to, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, the polyalkylene glycols, talcum, cellulose, glucose, sucrose and magnesium carbonate. The solid dosage forms may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the technique described in the U.S. Pat. Nos. 4,256,108; 4,166,452; and 4,265,874,

20

25

to form osmotic therapeutic tablets for control release. Liquid pharmaceutically administrable dosage forms can, for example, comprise a solution or suspension of one or more of the compounds of the present invention and optional pharmaceutical adjutants in a carrier, such as for example, water, saline, aqueous dextrose, glycerol, ethanol and the like, to thereby form a solution or suspension. If desired, the pharmaceutical composition to be administered may also contain minor amounts of nontoxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like. Typical examples of such auxiliary agents are sodium acetate, sorbitan monolaurate, triethanolamine, sodium acetate, triethanolamine oleate, etc. Actual methods of preparing

30

such dosage forms are known, or will be apparent, to those skilled in this art; for example, see Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., 16th Edition, 1980. The composition of the formulation to be administered, in any event, contains a quantity of one or more of the presently useful compounds in an amount effective to provide the desired therapeutic effect.

Parenteral administration is generally characterized by injection, either subcutaneously, intramuscularly or intravenously. Injectable formulations can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol and the like. In addition, if desired, the injectable pharmaceutical compositions to be administered may also contain minor amounts of non-toxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like.

The amount of the presently useful compound or compounds of the present invention administered is, of course, dependent on the therapeutic effect or effects desired, on the specific mammal being treated, on the severity and nature of the mammal's condition, on the manner of administration, on the potency and pharmacodynamics of the particular compound or compounds employed, and on the judgment of the prescribing physician. The therapeutically effective dosage of the presently useful compound or compounds is preferably in the range of about 0.5 ng/kg/day or about 1 ng/kg/day to about 100 mg/kg/day.

For ophthalmic application, solutions are often prepared using a physiological saline solution as a major vehicle. Ophthalmic solutions should preferably be maintained at a comfortable pH with an appropriate buffer system. The formulations may also contain conventional, pharmaceutically acceptable preservatives, stabilizers and surfactants.

Preservatives that may be used in the pharmaceutical compositions of the present invention include, but are not limited to, benzalkonium chloride, chlorobutanol, thimerosal, phenylmercuric acetate and phenylmercuric nitrate. A useful surfactant is, for example, Tween 80. Likewise, various useful vehicles may be used in the ophthalmic preparations of the present invention. These vehicles include, but are not limited to, polyvinyl alcohol,

povidone, hydroxypropyl methyl cellulose, poloxamers, carboxymethyl cellulose, hydroxyethyl cellulose and purified water.

5 Tonicity adjustors may be added as needed or convenient. They include, but are not limited to, salts, particularly sodium chloride, potassium chloride, mannitol and glycerin, or any other suitable ophthalmically acceptable tonicity adjustor.

10 Various buffers and means for adjusting pH may be used so long as the resulting preparation is ophthalmically acceptable. Accordingly, buffers include acetate buffers, citrate buffers, phosphate buffers and borate buffers. Acids or bases may be used to adjust the pH of these formulations as needed.

15 Similarly, an ophthalmically acceptable antioxidant for use in the present invention includes, but is not limited to, sodium metabisulfite, sodium thiosulfate, acetylcysteine, butylated hydroxyanisole and butylated hydroxytoluene.

Other excipient components which may be included in the ophthalmic preparations are chelating agents. A useful chelating agent is edentate disodium, although other chelating agents may also be used in place or in conjunction with it.

20

For topical use, creams, ointments, gels, solutions or suspensions, etc., containing the compound of the present invention are employed. Topical formulations may generally be comprised of a pharmaceutical carrier, cosolvent, emulsifier, penetration enhancer, preservative system, and emollient.

25

The actual dose of the compounds of the present invention depends on the specific compound, and on the condition to be treated; the selection of the appropriate dose is well within the knowledge of the skilled artisan.


30

The present invention is not to be limited in scope by the exemplified embodiments, which are only intended as illustrations of specific aspects of the invention. Various modifications of the invention, in addition to those disclosed herein, will be apparent to those skilled in the

art by a careful reading of the specification, including the claims, as originally filed. It is intended that all such modifications will fall within the scope of the appended claims.

What is claimed is:

1. A compound having the following formula:



5

wherein

X is O, NR₇ or (CH₂)_n, wherein n is 0 or an integer of 1 or 2;

- 10 Y is absent;

Z is O;

- 15 W is selected from the group consisting of alkyl and hydroxy, halogen, nitro, amino, and cyano-substituted alkyl or aryl;

R₁ is selected from the group consisting of OR₇, N(R₇)₂, and N(R₇)SO₂R₇;

- 20 R₂ is selected from the group consisting of H, hydroxy, alkyl, aryl, alkoxy, aryloxy, halogen, nitro, amino, cyano and hydroxy, halogen, nitro, amino and cyano-substituted alkyl, aryl, alkoxy or aryloxy;

R₄ is selected from the group consisting of H, NH₂, alkyl, nitrogen-substituted alkyl and halogen-substituted alkyl;

25

R₅ is selected from the group consisting of H, hydroxy, alkyl, aryl, alkoxy, aryloxy, halogen, nitro, amino, cyano and hydroxy, halogen, nitro, amino and cyano-substituted alkyl, aryl, alkoxy or aryloxy;

- 5 R₆ is selected from the group consisting of H, hydroxy, alkyl, aryl, alkoxy, aryloxy, halogen, nitro, amino, cyano and hydroxy, halogen, nitro, amino and cyano-substituted alkyl, aryl, alkoxy or aryloxy;

- R₇ is selected from the group consisting of H, hydrocarbyl and substituted hydrocarbyl,
 10 wherein alkyl refers to a straight-chain, branched or cyclic saturated aliphatic hydrocarbon having 1 to 12 carbons;
 aryl refers to an aromatic group which has at least one ring having a conjugated pi electron system which may be optionally substituted with one or more substituents selected from the group consisting of alkyl, hydroxyl, halogen, COOR⁷, NO₂, CF₃, N(R⁷)₂, CON(R⁷)₂, SR⁷,
 15 sulfoxy, sulfone, CN and OR⁷, wherein R⁷ is selected from the group consisting of H, hydrocarbyl and substituted hydrocarbyl;
 hydrocarbyl refers to a hydrocarbon radical having only carbon and hydrogen atoms, and wherein, the hydrocarbyl radical has from 1 to 20 carbon atoms; and
 substituted hydrocarbyl refers to a hydrocarbyl radical wherein one or more, but not all, of
 20 the hydrogen and/or the carbon atoms are replaced by a halogen, nitrogen, oxygen, sulfur or phosphorus atom or a radical including a halogen, nitrogen, oxygen, sulfur or phosphorus atom.

2. The compound of claim 1, wherein

- 25 R₁ is OH; or
 R₂ is selected from the group consisting of H, alkyl and halogen-substituted alkyl; or
 R₄ is selected from the group consisting of H, alkyl and halogen-substituted alkyl; or
 X is (CH₂)_n, wherein n is 0 or 1; or
 R₅ is chloro or bromo; or
 30 R₆ is H; or
 the compound is selected from the group consisting of:
 1-[(5-Bromo-2-{2-ethylbutyloxy}phenyl)methyl]-5-methyl-1H-pyrazole-4-methylenecarboxylic acid; and

1-[(5-Bromo-2-{2-ethylbutyloxy}phenyl)methyl]-5-methyl-1H-pyrazole-4-carboxylic acid.

3. The compound of claim 2, wherein W is selected from the group consisting of alkyl or branch chain alkyl wherein alkyl refers to a straight-chain, branched or cyclic saturated aliphatic hydrocarbon having 1 to 12 carbons.

4. The compound of claim 1 that is selected from the group consisting of:

1-[(5-Bromo-2-{2-ethylbutyloxy}phenyl)methyl]-5-methyl-1H-pyrazole-4-methylenecarboxylic acid;

1-[(5-Bromo-2-{2-ethylbutyloxy}phenyl)methyl]-5-methyl-1H-pyrazole-4-carboxylic acid;

1-[(5-Bromo-2-{2-ethylbutyloxy}phenyl)methyl]-3-methyl-1H-pyrazole-4-carboxylic acid;

1-[(5-chloro-2-{2-ethylbutyloxy}phenyl)methyl]-1H-pyrazole-4-carboxylic acid;

1-[(5-Chloro-2-{2-ethylbutyloxy}phenyl)methyl]-3,5-dimethyl-1H-pyrazole-4-carboxylic acid;

1-[(5-chloro-2-{2-ethylbutyloxy}phenyl)methyl]-3-propyl-1H-pyrazole-4-carboxylic acid;

1-[(5-chloro-2-{2-ethylbutyloxy}phenyl)methyl]-5-propyl-1H-pyrazole-4-carboxylic acid;

1-[(5-trifluoromethyl-2-{2-ethylbutyloxy}phenyl)methyl]-5-methyl-1H-pyrazole-4-carboxylic acid;

1-[(5-trifluoromethyl-2-{2-ethylbutyloxy}phenyl)methyl]-3-methyl-1H-pyrazole-4-carboxylic acid;

1-[(5-Chloro-2-{2-ethylbutyloxy}phenyl)methyl]-5-methyl-1H-pyrazole-4-carboxylic acid;

1-(5-chloro-2-isobutoxy-benzyl)-5-methyl-1H-pyrazole-4-carboxylic acid;

1-(5-chloro-2-cyclopentylmethoxy-benzyl)-5-methyl-1H-pyrazole-4-carboxylic acid;

1-(5-bromo-2-isobutoxy-benzyl)-5-methyl-1H-pyrazole-4-carboxylic acid;

5

1-[5-bromo-2-(2,2-dimethyl-propoxy) -benzyl]-5-methyl-1H-pyrazole-4-carboxylic acid;

1-[2-(2-ethyl-butoxy)-5-trifluoromethoxy-benzyl]-5-methyl-1H-pyrazole-4-carboxylic acid;
and,

10

5-amino-1-[5-bromo-2-(2-ethyl-butoxy)-benzyl]-1H-pyrazole-4-carboxylic acid.

5. A method of making a {1-2-[(hydrocarbyl or substituted hydrocarbyloxy)-benzyl] 1H-pyrazol- or alkyl-1H-pyrazol)-4-yl }-acetic or carboxylic acid which comprises hydrolyzing
15 the corresponding {1-2-[(hydrocarbyl or substituted hydrocarbyloxy)-benzyl]1H-pyrazol-4-yl}-acetic or carboxylic acid, alkyl ester to yield said {1-2-[(hydrocarbyl or substituted hydrocarbyloxy)-benzyl]1H-pyrazol-4-yl}-acetic or carboxylic acid,
wherein said {1-2-[(hydrocarbyl or substituted hydrocarbyloxy)-benzyl]1H-pyrazol-4-yl}-acetic or carboxylic acid is a {1-[halo or haloalkyl-2-(hydrocarbyloxy)-benzyl]-alkyl-1H-
20 pyrazol-4-yl}-acetic or carboxylic acid and
said {1-[halo or haloalkyl-2-(hydrocarbyloxy)-benzyl]-alkyl-1H-pyrazol-4-yl}-acetic or carboxylic acid is a {1-[5-halo or haloalkyl-2-(branched chain alkoxy)-benzyl]-3 and/or 5-alkyl-1H-pyrazol-4-yl}-acetic or carboxylic acid.

25 6. The compound of claim 1 for use in treating DP1, FP, EP1, TP and/or EP4 receptor mediated diseases or conditions, wherein
said condition or disease is related to inflammation; or
said DP1, FP, EP1, TP and/or EP4 receptor mediated condition or disease is selected from the group consisting of allergic conditions, asthma, allergic asthma, allergic rhinitis, uveitis and
30 related disorders, atherosclerosis, blood coagulation disorders, bone disorders, cancer, cellular neoplastic transformations, chronic obstructive pulmonary diseases and other forms of lung inflammation, congestive heart failure, diabetic retinopathy, diseases or conditions requiring a treatment of anti-coagulation, diseases requiring control of bone formation and

resorption, fertility disorders, gangrene, glaucoma, hyperpyrexia, immune and autoimmune diseases, inflammatory conditions, metastatic tumor growth, migraine, mucus secretion disorders, nasal congestion, nasal inflammation, occlusive vascular diseases, ocular hypertension, ocular hypotension, osteoporosis, rheumatoid arthritis , pain, perennial rhinitis,

5 pulmonary congestion, pulmonary hypotension, Raynaud's disease, rejection in organ transplant and by-pass surgery, respiratory conditions, hirsutism , rhinorrhea, shock, sleep disorders, and sleep-wake cycle disorders; or

for use as a surgical adjunct in ophthalmology for cataract removal and artificial lens insertion, ocular implant procedures, photorefractive radial keratotomy and other

10 ophthalmological laser procedures; or

for use as a surgical adjunct in a procedure involving skin incisions, relief of pain and inflammation and scar formation/keloids post-surgery, for treating sports injuries and general aches and pains in muscles and joints; or

said allergic condition is dermatological allergy; or an ocular allergy; or a respiratory allergy;

15 or

said condition or disease is selected from the group consisting of nasal congestion, rhinitis, and asthma; or

said condition or disease is related to pain; or

said condition or disease is selected from the group consisting of arthritis, migraine, and

20 headache; or

said condition or disease is associated with the gastrointestinal tract; or

said condition or disease is selected from the group consisting of peptic ulcer, heartburn, reflux esophagitis, erosive esophagitis, non-ulcer dyspepsia, infection by *Helicobacter pylori*, alrnyitis, and irritable bowel syndrome; or

25 said condition or disease is related to mucus secretion; or

said condition or disease is related to abdominal cramping; or

said condition or disease is irritable bowel syndrome; or

said condition or disease is a bleeding disorder; or

said condition or disease is a sleep disorder; or

30 said condition or disease is mastocytosis; or

said condition or disease is associated with elevated body temperature; or

said condition or disease is associated with ocular hypertension and glaucoma; or

said condition or disease is associated with ocular hypotension; or

said condition relates to surgical procedures to treat pain, inflammation and other unwanted sequelae wherein said surgical procedure includes incision, laser surgery or implantation; or said condition is related to pain and inflammation and post-surgical scar and keloid formation.

5

7. A pharmaceutical product comprising the compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein said product is packaged and labeled for the treatment or prevention of a disease or condition selected from the group consisting of uveitis, allergic conditions, asthma, allergic asthma, allergic rhinitis, atherosclerosis, blood coagulation disorders, bone disorders, cancer, cellular neoplastic transformations, chronic obstructive pulmonary diseases and other forms of lung inflammation, congestive heart failure, diabetic retinopathy, diseases or conditions requiring a treatment of anti-coagulation, diseases requiring control of bone formation and resorption, fertility disorders, hyperpyrexia, gangrene, glaucoma, hypothermia, immune and autoimmune diseases, inflammatory conditions, metastatic tumor growth, migraine, mucus secretion disorders, nasal congestion, nasal inflammation, occlusive vascular diseases, ocular hypertension, ocular hypotension, osteoporosis, pain, perennial rhinitis, pulmonary congestion, pulmonary hypotension, Raynaud's disease, rejection in organ transplant and by-pass surgery, respiratory conditions, rheumatoid arthritis, rhinorrhea, shock, sleep disorders, sleep-wake cycle disorders, sports injuries, muscle aches and pains, and surgical adjunct for minimizing pain, inflammation and scar/keloid formation.

10
15
20

8. A pharmaceutical composition comprising the compound of claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

25

FIGURE 1




FIGURE 2






FIGURE 3





(A)